{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2021_00016680", "CSN": null, "TRF": "ORD_1201785_01", "MRN": "45597873", "PhysicianId": "110128", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "894864", "clinicalId": "896269", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1201785_01", "SampleName": "US1160952.01", "Version": "0", "Sample": {"FM_Id": "ORD_1201785_01", "SampleId": "US1160952.01", "BlockId": "S110-24095A", "TRFNumber": "ORD_1201785_01", "TestType": "FoundationOne CDx             ", "SpecFormat": "FFPE", "ReceivedDate": "2021_09_30", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}]}, "TumorPurity": "60", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "S110-99728", "MRN": "48897873", "FullName": "\u5433\u6606\u548c", "FirstName": "Kun_Han", "LastName": "Wu", "SubmittedDiagnosis": "Metastatic carcinoma, Liver", "Gender": "Male", "DOB": "1951_08_04", "OrderingMD": "\u937e\u5b5d\u4ec1", "OrderingMDId": "110128", "Pathologist": "\u5468\u5fb7\u76c8", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Liver", "CollDate": "2021_08_19", "ReceivedDate": "2021-10-11 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Carcinoma, NOS"}, "PertinentNegatives": {"PertinentNegative": [{"Gene": "ATM"}, {"Gene": "BARD1"}, {"Gene": "BRCA1"}, {"Gene": "BRCA2"}, {"Gene": "BRIP1"}, {"Gene": "CDK12"}, {"Gene": "CHEK1"}, {"Gene": "CHEK2"}, {"Gene": "FANCL"}, {"Gene": "PALB2"}, {"Gene": "RAD51B"}, {"Gene": "RAD51C"}, {"Gene": "RAD51D"}, {"Gene": "RAD54L"}]}, "Summaries": {"alterationCount": "28", "clinicalTrialCount": "6", "resistiveCount": "0", "sensitizingCount": "0"}, "VariantProperties": {"VariantProperty": [{"geneName": "AXL", "isVUS": "true", "variantName": "V150A"}, {"geneName": "CCND2", "isVUS": "true", "variantName": "V240M"}, {"geneName": "FBXW7", "isVUS": "true", "variantName": "amplification"}, {"geneName": "KDM5A", "isVUS": "true", "variantName": "T741S"}, {"geneName": "KMT2A (MLL)", "isVUS": "true", "variantName": "Y2473C"}, {"geneName": "MLH1", "isVUS": "true", "variantName": "amplification"}, {"geneName": "MYD88", "isVUS": "true", "variantName": "amplification"}, {"geneName": "NBN", "isVUS": "true", "variantName": "amplification"}, {"geneName": "NKX2_1", "isVUS": "true", "variantName": "A63S"}, {"geneName": "PPARG", "isVUS": "true", "variantName": "amplification"}, {"geneName": "RAF1", "isVUS": "true", "variantName": "splice site 1418_1G>A"}, {"geneName": "REL", "isVUS": "true", "variantName": "N551S"}, {"geneName": "SETD2", "isVUS": "true", "variantName": "amplification"}, {"geneName": "TGFBR2", "isVUS": "true", "variantName": "amplification"}, {"geneName": "VHL", "isVUS": "true", "variantName": "amplification"}, {"geneName": "ZNF217", "isVUS": "true", "variantName": "rearrangement"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "MYCN", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "amplification"}}, "Interpretation": "MYCN encodes a MYC family protein; MYC gene products are thought to act as oncoproteins by preventing cell differentiation and promoting cell proliferation, in part by altering transcription of many target genes (Dang et al., 2006; 16904903, Liu et al., 2007; 18003922). MYCN has been reported to be amplified in cancer (Gao et al., 2013; 23550210), and may be biologically relevant in this context (Zack et al., 2013; 24071852, Beroukhim et al., 2010; 20164920). MYCN amplification has been reported in up to 4% of prostate adenocarcinoma cases (cBio_Taylor et al., 2010; 20579941, Cancer Genome Atlas Research Network., 2015; 26544944, Mosquera et al., 2013; 23358695, Beltran et al., 2011; 22389870) and in 15_40% of prostate neuroendocrine adenocarcinoma samples (cBio_Beltran et al., 2016; 26855148, Beltran et al., 2011; 22389870, Mosquera et al., 2013; 23358695). MYCN overexpression has been reported to be significantly more frequent in prostate neuroendocrine carcinoma as compared with prostate carcinoma; overexpression of MYCN in benign or prostate cancer cells induced the expression of various neuroendocrine markers (Beltran et al., 2011; 22389870). MYCN amplification has been implicated in disease progression in patients with prostate cancer (Mosquera et al., 2013; 23358695, Beltran et al., 2011; 22389870). On the basis of extensive preclinical data across multiple cancer types, tumors with MYCN amplification may be sensitive to CDK2 inhibitors (Horiuchi et al., 2012; 22430491, Goga et al., 2007; 17589519, Molenaar et al., 2009; 19525400, Delehouz\u00e9 et al., 2014; 24317512, Dolman et al., 2015; 26202950) or inhibitors of BET bromodomain_containing proteins (Puissant et al., 2013; 23430699, Baratta et al., 2015; 25535366, Venkataraman et al., 2014; 24796395, Wyce et al., 2013; 24009722, Henssen et al., 2015; 26631615). BET inhibitors are under investigation in clinical trials and have shown clinical activity in patients with acute myeloid leukemia, lymphoma, or NUT midline carcinoma (Dombret et al., 2014; ASH Abstract 117, Thieblemont et al., 2014; ASH Abstract 4417, Shapiro et al., 2015; AACR_NCI_EORTC Abstract A49). Extensive preclinical evidence in models of neuroblastoma also suggests that MYCN amplification may predict sensitivity to inhibitors of Aurora kinase A (Otto et al., 2009; 19111882, Hook et al., 2012; 22222631, Brockmann et al., 2013; 23792191, Faisal et al., 2011; 21885865, Hill et al., 2015; 25533335, Ham et al., 2016; 26859456, Gustafson et al., 2014; 25175806), although it should be noted that a Phase 1 study of the Aurora kinase A and B inhibitor AT9283 reported progressive disease (PD) in a patient with neuroblastoma harboring MYCN amplification and 1 mixed response and 1 PD in 2 patients with non_MYCN_amplified neuroblastoma (Moreno et al., 2015; 25370467). Further, another Phase 1 study evaluating the Aurora kinase A inhibitor alisertib in patients with neuroblastoma did not report a significant difference between those that were MYCN_amplified and those that were MYCN_non amplified (35.7% vs 16.7%; p=0.61)(Dubois et al., 2016; 26884555). Multiple preclinical experiments in models of neuroblastoma have also shown that MYCN amplification or overexpression, in the absence of concurrent mutations in TP53, is associated with sensitivity to MDM2 inhibitors (Chen et al., 2009; 19649205, Van Maerken et al., 2009; 19903807, He et al., 2011; 21862876, Petroni et al., 2011; 21173028, Gamble et al., 2012; 21725357). Newer approaches to target MYCN amplification in cancers, including inhibition of N_MYC expression and indirect targeting of N_MYC, are in preclinical development (Singhal et al., 2012; 22174364, Tonelli et al., 2012; 22065083).", "Include": "true", "ClinicalTrialNote": "MYCN amplification may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, particularly Aurora kinases A and B, of MDM2, and of BET bromodomain_containing proteins.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT03220347", "Include": "true"}, {"nctId": "NCT04556617", "Include": "true"}, {"nctId": "NCT03297424", "Include": "true"}, {"nctId": "NCT03611868", "Include": "true"}, {"nctId": "NCT04555837", "Include": "true"}, {"nctId": "NCT01434316", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "AR", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "amplification"}}, "Interpretation": "AR encodes the androgen receptor, a nuclear receptor that binds to testosterone and dihydroxytestosterone. AR is frequently amplified and overexpressed in castration_resistant prostate cancer (CRPC), also called hormone_refractory prostate cancer (Niraula et al., 2012; 22124843). Aberrant activation of AR through mutation and amplification of AR has been shown to be fundamental to prostate cancer progression; AR amplification is rare in hormone_naive prostate cancer (Merson et al., 2014; 24481405, Visakorpi et al., 1995; 7795646, Koivisto et al., 1997; 9000575, Bubendorf et al., 1999; 10029066, Linja et al., 2001; 11325816), but has been reported for 13_49% of patients with castration_resistant prostate cancer (CRPC) following progression on androgen_deprivation therapy or AR pathway inhibitors, such as abiraterone or enzalutamide (Palmberg et al., 2000; 11061898, Visakorpi et al., 1995; 7795646, Koivisto et al., 1997; 9000575, Haapala et al., 2007; 17217995, Schrecengost and Knudsen, 2013; 23806491, Schmidt and Tindall, 2013; 23565753, Grasso et al., 2012; 22722839, Taylor et al., 2010; 20579941, Azad et al., 2015; 25712683, Waltering et al., 2012; 22245783, Gross et al., 2013; ASCO Abstract 11047, Bubendorf et al., 1999; 10029066, Belic et al., 2018; 29574703, Wyatt et al., 2016; 27148695, Sonpavde et al., 2019; 30620391). Some studies have shown that AR amplification was significantly more common for patients who progressed on enzalutamide than for those who progressed on abiraterone or other agents (Azad et al., 2015; 25712683, Aggarwal et al., 2015; ASCO GU Abstract 5068, Attard et al., 2009; 19339269). AR copy number gain is associated with increased Gleason score, increased baseline prostate_specific antigen (PSA), more advanced clinical stage, and disease progression (Waltering et al., 2012; 22245783, Merson et al., 2014; 24481405, Kohli et al., 2020; 32268276), and is significantly associated with worse OS in castration_resistant prostate cancer (CRPC) (Annala et al., 2021; 33836265, Kubota et al., 2021; 33675416, Kohli et al., 2020; 32268276, Kohli et al., 2018; 29858592, Conteduca et al., 2018; 30773204). For patients with CRPC treated with enzalutamide or abiraterone, AR copy number gain or amplification has been associated with worse outcomes (Annala et al., 2021; 34083234, Del Re et al., 2021; 33500577, Conteduca et al., 2017; 28472366, Tolmeijer et al., 2020; DOI: 10.1200/PO.20.00084, Azad et al., 2015; 25712683, Romanel et al., 2015; 26537258, Salvi et al., 2016; 27191887); however, AR amplification does not always correlate with poor outcomes on these treatments (Belic et al., 2018; 29574703, Annala et al., 2018; 29367197). In the context of chemotherapy, patients with AR_amplified castration_resistant prostate cancer (CRPC) experienced longer OS on docetaxel compared with enzalutamide or abiraterone (Conteduca et al., 2018; 30773204). In a meta_analysis study, AR gain did not affect OS and PFS for patients treated with first_line docetaxel or second_line or third_line cabazitaxel, but was associated with reduced response in later lines of docetaxel (Tolmeijer et al., 2020; DOI: 10.1200/PO.20.00084). For patients with poor_prognosis CRPC treated with either cabazitaxel followed by androgen receptor pathway inhibitors (ARPIs) or ARPIs followed by cabazitaxel, AR amplification was significantly associated with shorter time to progression for both ARPIs and cabazitaxel, without significant difference observed between the 2 methods of treatment (Annala et al., 2021; 33836265). AR amplification has also been associated with poor outcomes for patients with metastatic CPRC treated with radioligand therapy 177Lu_PSMA_617 (Paganelli et al., 2020; EANM Abstract OP_980). Antiandrogens such as apalutamide, bicalutamide, cyproterone, darolutamide, enobosarm, enzalutamide, flutamide, and nilutamide directly target AR, whereas hormone therapies such as the CYP17A1 inhibitor abiraterone and luteinizing hormone_releasing hormone agonists or antagonists modulate androgen production (Patel et al., 2013; 23819055, Chowdhury and Kirby, 2013; 23724747, Ahmed et al., 1983; 6135909, Smith et al., 2018; 29420164, Fizazi et al., 2019; 30763142, Fizazi et al., 2014; 24974051, Soifer et al., 2012; 22174412, Sartor, 2011; 21808270, Bolton and Lynch 2018; 29438592, Hird et al., 2020; 32278840, Palmieri et al., 2020; SABCS Abstract PD8_10). Resistance to androgen deprivation therapy (ADT) commonly occurs in prostate cancer through mechanisms such as increased AR expression, AR activation by tyrosine kinase_dependent signaling, alterations in AR co_activators, expression of alternatively spliced isoforms of AR mRNAs (AR_Vs), and extragonadal synthesis of androgenic compounds (van der Steen et al., 2013; 23863692, Lee et al., 2013; 24019458, Gowda et al., 2013; 23989930, Liu et al., 2014; 23851510, Wadosky et al., 2016; 27487144). AR signaling may promote radioresistance in prostate cancer by transcriptionally upregulating DNA repair genes (Bartek et al., 2013; 24203954). There is preclinical evidence that development of resistance to anti_AR therapies, such as abiraterone and enzalutamide, may engender cross_resistance to the taxanes docetaxel and cabazitaxel (van Soest et al., 2013; 24200698); however, certain AR_Vs may remain sensitive to taxanes (Scher et al., 2016; 27262168, Antonarakis et al., 2015; 26181238). Approaches currently in clinical and preclinical development for prostate cancer include therapies that target AR nuclear translocation and degradation pathways (Loddick et al., 2013; 23861347, Rathkopf et al., 2013; 24002508, Smith et al., 2016; 27160947, Rathkopf et al., 2017; 28213364, Soh et al., 2013; 24042123, Bianchini et al., 2013; 24169353, Li et al., 2013; 23939374, Petrylak et al., 2020; ASCO Abstract 3500), combination approaches to suppress androgen biosynthesis (McKay et al., 2016; 27683182), and the use of bromodomain and extraterminal (BET) inhibitors that disrupt the interaction between AR and BRD4 (Asangani et al., 2014; 24759320, Asangani et al., 2016; 26792867, Faivre et al., 2017; 27707886); the latter approach has potential to target AR_Vs (Chan et al., 2015; 25908785, Asangani et al., 2016; 26792867, Faivre et al., 2017; 27707886). The BET inhibitor mivebresib led to an SD rate of 60% (6/10) for patients with genomically unselected prostate cancer who had progressed on multiple standard of care therapies (Piha_Paul et al., 2019; 31420359). Galeterone, a multifunctional AR inhibitor, has been evaluated in several Phase 1 and 2 studies and has been found to reduce prostate_specific antigen levels for 49_73% of patients, although clinical trials of this reagent are not recruiting patients (Antonarakis et al., 2016; ASCO Abstract TPS5085, Montgomery et al., 2016; 26527750). Extensive clinical data have demonstrated that AR amplification may confer resistance to androgen deprivation therapy (Visakorpi et al., 1995; 7795646, Koivisto et al., 1997; 9000575, Wakostky and Koochekpour, 2016; 27487144, Waltering et al., 2012; 22245783) or androgen receptor signaling inhibitors (ARSIs) such as abiraterone and enzalutamide (Du et al., 2020; 32203070, Dong et al., 2021; 33990090, Kohli et al., 2020; 32268276, McKay et al., 2021; 33849963), although a few studies suggested that AR amplification confers resistance only to enzalutamide but not to abiraterone (Sakamoto et al., 2019; ASCO GI 314), or its presence does not preclude response to ARSIs (Annala et al., 2018; 29367197, Aggarwal et al., 2015; ASCO GU Abstract 5068).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "GNAS", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "true", "name": "amplification"}}, "Interpretation": "GNAS encodes the alpha subunit of the stimulatory G protein (Gs_alpha) (Hayward et al., 1998; 9860993). Gs_alpha is a guanine_nucleotide binding protein (G protein) that is involved in hormonal regulation of adenylate cyclase (Hayward et al., 1998; 9860993). GNAS has been reported to be amplified in cancer (Gao et al., 2013; 23550210) and may be biologically relevant in this context (Zack et al., 2013; 24071852, Beroukhim et al., 2010; 20164920). GNAS alterations that have been shown to result in constitutive activation of adenylyl cyclase and an increase in cellular cAMP concentration (Masters et al., 1989; 2549064, Graziano and Gilman, 1989; 2549065, Jang and Juhnn, 2001; 11322485, Landis et al., 1989; 2549426, Tobar_Rubin et al., 2013; 23288949, Mariot et al., 2011; 20887824) are predicted to be activating. Mutations at R201 specifically are commonly associated with McCune_Albright syndrome, a disease that can co_occur with various cancers in patients with GNAS activating mutations (Weinstein et al., 1991; 1944469, Collins et al., 2003; 12970318, Nault et al., 2012; 21835143). The highest incidences of GNAS mutations have been reported in intraductal papillary mucinous neoplasms (40_66%)(Furukawa et al., 2011; 22355676, Wu et al., 2011; 21775669) and appendiceal mucinous neoplasms (50_72%)(Nishikawa et al., 2013; 23403822, Singhi et al., 2014; 24925222) as well as in tumors affecting the peritoneum (22%), pituitary gland (20%), bone (15%), pancreas (12%), and small intestine (12%)(COSMIC, 2021)(Tate et al., 2019; 30371878). Amplification of GNAS has been reported in ovarian epithelial carcinomas (12_30%)(Cancer Genome Atlas Research Network., 2011; 21720365, Kan et al., 2010; 20668451, Tominaga et al., 2010; 20537689), colorectal adenocarcinoma (9%)(Cancer Genome Atlas Network., 2012; 22810696), stomach adenocarcinoma (7%)(Cancer Genome Atlas Research Network., 2014; 25079317), lung adenocarcinoma (6.5%)(Cancer Genome Atlas Research Network., 2014; 25079552), breast invasive carcinoma (6.5%)(Cancer Genome Atlas Network., 2012; 23000897), pancreatic adenocarcinoma (6%)(Bio_Witkiewicz et al., 2015; 25855536), and sarcomas (5.8%)(cBio_Barretina et al., 2010; 20601955). GNAS mutations are rare in hematological malignancies generally (COSMIC, 2021)(Tate et al., 2019; 30371878, cBio_Lohr et al., 2014; 24434212, Chapman et al., 2011; 21430775). Activating GNAS mutations have been identified in gastrointestinal polyps in 75% (3/4) of patients with McCune_Albright syndrome (Zacharin et al., 2011; 21357941). Amplification of GNAS has been associated with shorter progression_free survival in patients with ovarian cancer (Kan et al., 2010; 20668451, Tominaga et al., 2010; 20537689), while activating GNAS mutations have been correlated with tumor progression and poor prognosis in patients with gastric cancer (Alakus et al., 2009; 20027678). There are no therapies targeted to GNAS mutation in cancer. However, there is limited data indicating that a patient with appendiceal adenocarcinoma and a GNAS mutation (R201H) benefited from trametinib for 4 months (Ang et al., 2017; 28868010). Additionally, a patient with GNAS_mutated Erdheim_Chester disease exhibited a PR following treatment with single_agent trametinib (Saunders et al., 2019; 31740567).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "IRS2", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "amplification"}}, "Interpretation": "IRS2 encodes the protein insulin receptor substrate 2, which is a cytoplasmic signaling molecule that links insulin receptor activation to downstream effectors, including the PI3K_mTOR pathway (White, 2002; 12169433). IRS2 amplification has been shown to correlate with increased mRNA expression levels (Day et al., 2013; 23594372, Huang et al., 2015; 25527633). IRS2 copy number gain has been reported most commonly in colorectal cancer (CRC), with a frequency of 8_26% across several datasets (cBio_Robinson et al., 2015; 26000489, cBio_Kumar et al., 2016; 26928463, Huang et al., 2015; 25527633, Day et al., 2013; 23594372). IRS2 amplification has been observed less frequently in bladder urothelial carcinomas (4.7%)(Cancer Genome Atlas Research Network., 2014; 24476821), sarcomas (3.9%)(cBio_Barretina et al., 2010; 20601955), stomach adenocarcinomas (3.8%)(Cancer Genome Atlas Research Network., 2014; 25079317), and hepatocellular carcinomas (1.3%)(cBio_Ahn et al., 2014; 24798001). Increased IRS2 protein expression has been reported in some tumor types, including 88% (46/53) of malignant peripheral nerve sheath tumors (Shaw et al., 2012; 22287730). Several preclinical studies in breast cancer have shown that IRS2 expression is associated with metastatic behavior (Becker et al., 2016; 26991655, de Blaqui\u00e8re et al., 2009; 19261680, Gibson et al., 2007; 17361103, Baserga et al., 2009; 19243297); another study demonstrated that IRS2 protein levels were low in a panel of ductal carcinoma in situ but increased significantly in relation to tumor invasiveness (Porter et al., 2013; 23562473). In CRC, however, no difference was found in the prevalence of IRS2 amplification between primary and metastatic colorectal tumors (Huang et al., 2015; 25527633). Despite this finding, elevated IRS2 has been shown to correlate with CRC disease progression (Day et al., 2013; 23594372). There are no therapies to directly target IRS2 amplification. However, preclinical studies using breast and CRC cell lines suggest that copy number gain and/or high levels of IRS2 may confer sensitivity to IGF1R inhibitors (Zha et al., 2009; 19671761, Huang et al., 2015; 25527633). Clinical trials of IGF1R inhibitors are in progress in multiple tumor types.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "MS_Stable", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "MS_Stable"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSI has been reported in 3.1_14.6% of prostate cancer samples (Hall et al., 2016; ASCO Abstract 1523, Cheng et al., 2016; ASCO Abstract 251)(Pritchard et al., 2014; 25255306, Schwarzenbach et al., 2008; 18336598, Suzuki et al., 1995; 7493915). A study of prostate cancer in hereditary nonpolyposis colorectal cancer (HNPCC) families reported MSI_H in 4_50% of cases (Dominguez_Valentin et al., 2016; 27013479, Rosty et al., 2014; 25117503, Ahman et al., 2001; 11251526). For patients with advanced prostate cancer, dMMR/MSI status was associated with shorter median OS compared with patients with proficient MMR (3.8 vs. 7.0 years) by univariate and multivariate analysis (adjusted HR=4.09; P=0.005)(Rodrigues et al., 2018; 30382943). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "RAF1", "Include": "true", "Alterations": {"Alteration": [{"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "amplification"}}, "Interpretation": "RAF1 encodes c_RAF, a member of the RAF family of signaling kinases (Gollob et al., 2006; 16890795). These kinases are downstream of RAS and activate the MEK_ERK signaling pathway that promotes cell proliferation and survival (Maurer et al., 2011; 21577205). RAF1 has been reported to be amplified in cancer (Gao et al., 2013; 23550210) and may be biologically relevant in this context (Zack et al., 2013; 24071852, Beroukhim et al., 2010; 20164920). RAF1 alterations that have been characterized as activating, as observed here, are predicted to be oncogenic (Imielinski et al., 2014; 24569458, Light et al., 2002; 12077328, Kubicek et al., 2002; 11756411, Balan et al., 2006; 16407412, Deng et al., 2013; 23529931, Deng et al., 2013; 23391722, Pandit et al., 2007; 17603483, Wu et al., 2011; 21339642, Wu et al., 2012; 22826437, Atefi et al., 2016; 27273450, Dhillon et al., 2002; 11971957, Michaud et al., 1995; 7760835, Molzan et al., 2010; 20679480, Antony et al., 2013; 23737487, Razzaque et al., 2007; 17603482, Kobayashi et al., 2010; 20052757). RAF1 amplification has been reported in 0.7% of prostate adenocarcinomas analyzed in cBioPortal (Aug 2021)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). In one study, RAF1 copy number gain was reported in 15% of prostate carcinomas (Ren et al., 2012; 22833462). RAF1 mutations have been reported in 2.0% of prostate carcinoma samples analyzed in COSMIC (Aug 2021)(Tate et al., 2019; 30371878). Polymorphisms in RAF1 have been associated with prostate cancer development (Chen et al., 2013; 24223781). Published data investigating the prognostic implications of RAF1 alterations in prostate cancer are generally limited (PubMed, Mar 2021). One study reported an association between increased RAF1 expression and earlier relapse in androgen_insensitive prostate cancer (Mukherjee et al., 2005; 15666389). In another study, RAF1 fusions were associated with castration_resistance and features of aggressiveness, including high Gleason score (Palanisamy et al., 2010; 20526349). RAF1 activating mutations may predict sensitivity to MEK inhibitors. A patient with mixed histiocytosis harboring an activating RAF1 mutation exhibited a CR by PET response criteria to the MEK inhibitor cobimetinib (Diamond et al., 2019; 30867592). RAF1 amplification may predict sensitivity to pan_RAF inhibitors. The addition of sorafenib to chemotherapy improved PFS for patients with melanoma and RAF1 copy number gains (HR=0.37, p=0.025) in a retrospective analysis (Wilson et al., 2015; 26307133). A retrospective study reported RAF1 expression as a predictor of improved OS (HR=1.84) and tumor_free survival (HR=1.32) for patients with hepatocellular carcinoma treated with adjuvant sorafenib in multivariate analyses (Lei et al., 2016; 26981887).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}, {"Name": "E478K", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "E478K"}}, "Interpretation": "RAF1 encodes c_RAF, a member of the RAF family of signaling kinases (Gollob et al., 2006; 16890795). These kinases are downstream of RAS and activate the MEK_ERK signaling pathway that promotes cell proliferation and survival (Maurer et al., 2011; 21577205). RAF1 has been reported to be amplified in cancer (Gao et al., 2013; 23550210) and may be biologically relevant in this context (Zack et al., 2013; 24071852, Beroukhim et al., 2010; 20164920). RAF1 alterations that have been characterized as activating, as observed here, are predicted to be oncogenic (Imielinski et al., 2014; 24569458, Light et al., 2002; 12077328, Kubicek et al., 2002; 11756411, Balan et al., 2006; 16407412, Deng et al., 2013; 23529931, Deng et al., 2013; 23391722, Pandit et al., 2007; 17603483, Wu et al., 2011; 21339642, Wu et al., 2012; 22826437, Atefi et al., 2016; 27273450, Dhillon et al., 2002; 11971957, Michaud et al., 1995; 7760835, Molzan et al., 2010; 20679480, Antony et al., 2013; 23737487, Razzaque et al., 2007; 17603482, Kobayashi et al., 2010; 20052757). RAF1 amplification has been reported in 0.7% of prostate adenocarcinomas analyzed in cBioPortal (Aug 2021)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). In one study, RAF1 copy number gain was reported in 15% of prostate carcinomas (Ren et al., 2012; 22833462). RAF1 mutations have been reported in 2.0% of prostate carcinoma samples analyzed in COSMIC (Aug 2021)(Tate et al., 2019; 30371878). Polymorphisms in RAF1 have been associated with prostate cancer development (Chen et al., 2013; 24223781). Published data investigating the prognostic implications of RAF1 alterations in prostate cancer are generally limited (PubMed, Mar 2021). One study reported an association between increased RAF1 expression and earlier relapse in androgen_insensitive prostate cancer (Mukherjee et al., 2005; 15666389). In another study, RAF1 fusions were associated with castration_resistance and features of aggressiveness, including high Gleason score (Palanisamy et al., 2010; 20526349). RAF1 activating mutations may predict sensitivity to MEK inhibitors. A patient with mixed histiocytosis harboring an activating RAF1 mutation exhibited a CR by PET response criteria to the MEK inhibitor cobimetinib (Diamond et al., 2019; 30867592). RAF1 amplification may predict sensitivity to pan_RAF inhibitors. The addition of sorafenib to chemotherapy improved PFS for patients with melanoma and RAF1 copy number gains (HR=0.37, p=0.025) in a retrospective analysis (Wilson et al., 2015; 26307133). A retrospective study reported RAF1 expression as a predictor of improved OS (HR=1.84) and tumor_free survival (HR=1.32) for patients with hepatocellular carcinoma treated with adjuvant sorafenib in multivariate analyses (Lei et al., 2016; 26981887).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}]}, "ReferenceLinks": null}, {"Name": "SF3B1", "Include": "true", "Alterations": {"Alteration": {"Name": "E622D", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "E622D"}}, "Interpretation": "SF3B1 encodes a subunit of the spliceosome, the complex that is responsible for the splicing of pre_mRNA molecules to create mature messenger RNA (Wang et al., 1998; 9585501, Quesada et al., 2011; 22158541, Wang et al., 2011; 22150006, Visconte et al., 2012; 22826563). SF3B1 mutations predominantly occur in HEAT domains 5_7 at codons 625, 662, 666, and 700 (Hahn et al., 2011; 22200771, Rossi et al., 2011; 22039264, Yang et al., 2013; 23390883, Patnaik et al., 2012; 22096241, Maguire et al., 2015; 25424858, Wan et al., 2013; 23568491), which result in neomorphic activity that upregulates aberrant mRNA splicing (Gentien et al., 2014; 24434863, De Boever et al., 2015; 2576898, Darman et al., 2015; 26565915, Alsafadi et al., 2016; 26842708). The consequences of SF3B1 alterations outside of these sites have not been extensively characterized. In the context of solid tumors, SF3B1 mutation has been reported in adenoid cystic carcinomas of the salivary gland (4%, 1/24) (Stephens et al., 2013; 23778141) and breast (Martelotto et al., 2015; 26095796) as well as in pancreatic carcinoma (Biankin et al., 2012; 23103869), glioblastoma, and renal clear cell carcinoma (Xie et al., 2014; 25326804). Mutation of SF3B1 was found to be recurrent in several breast carcinoma subtypes (Banerji et al., 2012; 22722202, Ellis et al., 2012; 22722193, Cancer Genome Atlas Network et al., 2012; 23000897), and in unselected breast cancers, it correlated with ER_positivity and frequent co_occurrence with AKT1 and PIK3CA mutations (Maguire et al., 2015; 25424858, Ellis et al., 2012; 22722193). The hot spot mutation K700E was found in 16% (3/19) of papillary and 6% of breast mucinous carcinomas (Maguire et al., 2015; 25424858). In solid tumors, the prognostic implications of SF3B1 alterations are dependent on disease context. In a study of 3282 breast cancer cases, SF3B1 mutation was significantly associated with a poor prognosis for patients with luminal B and progesterone receptor (PR)_negative subtypes of disease (Fu et al., 2017; 29383138). For patients with hepatocellular carcinoma, one study showed that SF3B1 mutation was associated with an advanced stage of disease (Nault et al., 2020; 31206197). However, in one study of primary uveal melanoma, SF3B1 mutation was correlated with improved PFS (Furney et al., 2013; 23861464). Preclinical studies suggest that mutations in genes encoding spliceosome components, including SF3B1, may confer sensitivity to spliceosome inhibitors (Obeng et al., 2016; 27622333, Lee et al., 2016; 27135740, Yoshimi et al., 2017; 27836865, Lee et al., 2016; 27603132, Singh et al., 2020; 32076118). In preclinical models, SF3B1 mutation leads to DNA damage and ATR_CHK1 pathway activation, increasing sensitivity to ATR and CHK1 inhibitors (Singh et al., 2020; 32076118). However, clinical data supporting SF3B1 as biomarkers for the efficacy of these approaches is lacking. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "TP53", "Include": "true", "Alterations": {"Alteration": {"Name": "splice site 376_1G>C", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "splice site 376_1G>C"}}, "Interpretation": "Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers (Brown et al., 2009; 19935675). Alterations such as seen here may disrupt TP53 function or expression (Joerger and Fersht, 2008; 18410249, Kato et al., 2003; 12826609, Kamada et al., 2011; 20978130, Zerdoumi et al., 2017; 28472496, Yamada et al., 2007; 17690113). TP53 mutations have been reported in 18_40% of prostate cancers (Kumar et al., 2011; 21949389, Beltran et al., 2013; 22981675). Overexpression of p53, which is indicative of TP53 dysregulation, has been reported to be significantly more common in late_stage and hormone_refractory prostate cancers and has been found to be associated with prostate_specific antigen (PSA) recurrence in low_ and intermediate_grade prostate cancer (Schlomm et al., 2008; 18552821). TP53 loss has been found to be associated with prostate cancer_specific mortality in univariate analysis (Liu et al., 2013; 23609948). There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib (Hirai et al., 2010; 20107315, Bridges et al., 2011; 21799033, Rajeshkumar et al., 2011; 21389100, Osman et al., 2015; 25504633), or p53 gene therapy and immunotherapeutics such as SGT_53 (Xu et al., 2002; 12489850, Xu et al., 2001; 11713371, Camp et al., 2013; 23470564, Kim et al., 2015; 25240597, Pirollo et al., 2016; 27357628) and ALT_801 (Hajdenberg et al., 2012; ASCO Abstract e15010). In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% (17/176) and SDs in 53.4% (94/176) of patients with solid tumors; the response rate was 21.1% (4/19) for patients with TP53 mutations versus 12.1% (4/33) for patients who were TP53 wild_type (Leijen et al., 2016; 27601554). A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 31.9% (30/94, 3 CR) ORR and a 73.4% (69/94) DCR for patients with platinum_refractory TP53_mutated ovarian, Fallopian tube, or peritoneal cancer (Moore et al., 2019; ASCO Abstract 5513). A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 42.9% (9/21, 1 CR) ORR and a 76.2% (16/21) DCR for patients with platinum_refractory TP53_mutated ovarian cancer (Leijen et al., 2016; 27998224). The combination of adavosertib with paclitaxel and carboplatin for patients with TP53_mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone (Oza et al., 2015; ASCO Abstract 5506). In the Phase 2 VIKTORY trial, patients with TP53_mutated metastatic and/or recurrent gastric cancer experienced a 24.0% (6/25) ORR with adavosertib combined with paclitaxel (Lee et al., 2019; 31315834). A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71.4% (5/7) response rate for patients with TP53 alterations (Mendez et al., 2018; 29535125). In a Phase 1b clinical trial of SGT_53 in combination with docetaxel for patients with solid tumors, 75.0% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage (Pirollo et al., 2016; 27357628). Additionally, the combination of a CHK1 inhibitor and irinotecan reportedly reduced tumor growth and prolonged survival in a TP53_mutated, but not TP53_wild_type, breast cancer xenotransplant mouse model (Ma et al., 2012; 22446188). ATR inhibitor treatment of chronic lymphocytic leukemia (CLL) cells with biallelic inactivation of TP53 suppressed cell viability, promoted DNA damage, and attenuated xenograft growth in preclinical studies (Kwok et al., 2016; 26563132, Boudny et al., 2019; 30975914); however, ATR inhibitors as monotherapy had little effect on these parameters in solid tumor models in other preclinical studies (Dillon et al., 2017; 28062704, Middleton et al., 2018; 30127241). Therefore, it is unclear whether TP53 inactivation predicts sensitivity to ATR inhibition. Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li_Fraumeni syndrome and the early onset of many cancers (Bougeard et al., 2015; 26014290, Sorrell et al., 2013; 23355100, Nichols et al., 2001; 11219776), including sarcomas (Kleihues et al., 1997; 9006316, Gonzalez et al., 2009; 19204208). Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000 (Lalloo et al., 2003; 12672316) to 1:20,000 (Gonzalez et al., 2009; 19204208). For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30 (Mandelker et al., 2019; 31050713). In the appropriate clinical context, germline testing of TP53 is recommended. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Mutation Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "04", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "04"}}, "Interpretation": "Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB level associated with lower rates of clinical benefit from treatment with PD_1_ or PD_L1_targeting immune checkpoint inhibitors compared with patients with tumors harboring higher TMB levels, based on several studies in multiple solid tumor types (Goodman et al., 2017; 28835386, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947). Prostate acinar adenocarcinoma harbors a median TMB of 2.7 mutations per megabase (muts/Mb), and 3.4% of cases have high TMB (>20 muts/Mb) (FMI_Chalmers et al., 2017; 28420421). Prostate cancer has been reported to harbor a relatively low TMB among solid tumors (Lawrence et al., 2013; 23770567, Alexandrov et al., 2013; 23945592), with approximately 0.5_1.5 (muts/Mb) in localized tumor samples (Barbieri et al., 2012; 22610119, Baca et al., 2013; 23622249, Cancer Genome Atlas Research Network., 2015; 26544944), and a higher but still low TMB of 2_5 muts/Mb in metastatic, castration_resistant prostate cancer (mCRPC) samples (Grasso et al., 2012; 22722839, Gundem et al., 2015; 25830880, cBio_Robinson et al., 2015; 26000489). One study reported that 4 of 150 (2.7%) mCRPC cases harbored high TMB (nearly 50 muts/Mb), which was due to defects in mismatch repair genes MLH1 and MSH2 in 3 of the 4 cases (cBio_Robinson et al., 2015; 26000489). The effects of hypermutation on prognosis and clinical features in prostate cancer have not been extensively investigated (PubMed, Feb 2021). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In multiple pan_tumor studies, higher TMB has been reported to be associated with increased ORR and OS from treatment with immune checkpoint inhibitors (Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947). Higher TMB was found to be significantly associated with improved OS upon immune checkpoint inhibitor treatment for patients with 9 types of advanced tumors (Samstein et al., 2019; 30643254). Analyses across several solid tumor types reported that patients with higher TMB (defined as \u226516_20 Muts/Mb) achieved greater clinical benefit from PD_1 or PD_L1_targeting monotherapy, compared with patients with higher TMB treated with chemotherapy (Legrand et al., 2018; ASCO Abstract 12000) or those with lower TMB treated with PD_1 or PD_L1_targeting agents (Goodman et al., 2017; 28835386). However, the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors found significant improvement in ORR for patients with TMB \u226510 Muts/Mb (based on this assay or others) compared to those with TMB <10 Muts/Mb, in a large cohort that included multiple tumor types; similar findings were observed in the KEYNOTE 028 and 012 trials (Marabelle et al., 2020; 32919526, Cristescu et al., 2018; 30309915). Together, these studies suggest that patients with TMB \u226510 Muts/Mb may derive clinical benefit from PD_1 or PD_L1 inhibitors. The Phase 2 CheckMate 650 trial of nivolumab and ipilimumab treatment for patients with metastatic castration_resistant prostate cancer reported that patients harboring above the median study TMB experienced increased ORR and PSA responses (Sharma et al., 2020; 32916128).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "VHL", "Include": "true", "Alterations": {"Alteration": {"Name": "rearrangement exon 3", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "rearrangement exon 3"}}, "Interpretation": "VHL encodes the protein pVHL (von Hippel_Lindau tumor suppressor), which is frequently inactivated, either via mutation or hypermethylation, in clear cell renal cell carcinoma (ccRCC) and plays an important role in its pathogenesis (Li and Kaelin, 2011; 21763962). Inactivating mutations in VHL lead to dysregulation of critical downstream growth regulators, especially members of the HIF family and VEGF (Kaelin and Ratcliffe, 2008; 18498744, Gnarra et al., 1996; 8855222). Alterations such as seen here may disrupt VHL function or expression (Albers et al., 2013; 23606570, Asakawa et al., 2012; 22462637, Banks et al., 2006; 16488999, Bond et al., 2011; 21454469, Clifford et al., 2001; 11331613, Cockman et al., 2000; 10823831, Corn et al., 2003; 14556007, Dandanell et al., 2012; 22799452, Feldman et al., 1999; 10635329, Feldman et al., 2003; 14636579, Hansen et al., 2002; 11865071, Hoffman et al., 2001; 11331612, Khacho et al., 2008; 17967880, Kibel et al., 1995; 7660130, Knauth et al., 2006; 16261165, Lewis and Roberts., 2004; 14691445, Li et al., 2002; 11739384, Li et al., 2002; 12056827, Liu and Nussinov, 2009; 19798438, Losonczy et al., 2013; 23298237, Maher et al., 1996; 8730290, McClellan et al., 2005; 15935760, Metzger and Michaelis, 2009; 19073890, Miller et al., 2005; 15611064, Moore et al., 2011; 22022277, Neumann et al., 1995; 7563486, Ohh et al., 1999; 10587522, Ohh et al., 2000; 10878807, Olschwang et al., 1998; 9829912, Patocs et al., 2008; 18416845, Rechsteiner et al., 2011; 21715564, Richards, 2001; 14987375, Ritter et al., 1996; 8772572, Schoenfeld et al., 2000; 10900011, Shmueli et al., 2013; 23840444, Siu et al., 2011; 21362373, Weirich et al., 2002; 12414898, Zbar et al., 1996; 8956040, Zhou et al., 2004; 14973063). VHL is frequently mutated in renal cell carcinomas, but VHL mutation has been detected in fewer than 1% of prostate adenocarcinoma cases (cBio_Barbieri et al., 2012; 22610119, cBio_Baca et al., 2013; 23622249, Cancer Genome Atlas Research Network., 2015; 26544944). Published data investigating the prognostic implications of VHL alteration in prostate carcinomas are limited (PubMed, Feb 2021). Various strategies are under clinical investigation to block pathways downstream of inactivated VHL, including HIF, VEGF, and mTOR. The multikinase inhibitor sunitinib, which has activity against VEGFRs and other targets, is approved to treat several tumor types and has shown strong efficacy in patients with VHL disease (Jimenez et al., 2009; 19017755, Kim et al., 2013; 24454008, Tsimafeyeu, 2015; 26881543, Babinska et al., 2015; 26812297, Kobayashi et al., 2016; 26984080). Several clinical trials found response rates up to 64% and disease control rates up to 90% (Matin et al., 2010; ASCO Abstract 3040, Jonasch et al., 2011; 22105611, Roma et al., 2015; 25391617). However, multiple clinical studies of sunitinib in patients with renal cell carcinoma reported that mutation or inactivation of the VHL gene is not significantly associated with therapeutic response or survival (Saez et al., 2012; ASCO Abstract 4630, Rini et al., 2006; 16827904, Choueiri et al., 2008; 18635227, Motzeret al., 2014; 25100134). Other agents that inhibit VEGFRs, including the multikinase inhibitors sorafenib, axitinib, pazopanib, regorafenib, cabozantinib, and vandetanib; the anti_VEGFR2 antibody ramucirumab; and the mTOR inhibitors everolimus and temsirolimus, are also approved in multiple tumor types. However, studies have similarly shown that VHL mutation or inactivation does not correlate with responses to these agents (Hutson et al., 2008; ASCO Abstract 5046, Choueiri et al., 2008; 18635227, Cho et al., 2007; 17956710, Choueiri et al., 2013; 23881929). Therefore, it is unclear whether these therapeutic strategies would be beneficial in this case. The HIF2a inhibitor belzutifan achieved an ORR of 36% in a clinical trial for VHL disease_associated clear cell renal cell carcinoma (Srinivasan et al., 2021; ASCO Abstract 4555). Responses were also seen in other VHL mutation_associated tumor types, including CNS hemangioblastomas and pancreatic neuroendocrine tumors; however, it was not determined whether VHL inactivation was significantly associated with these responses (Srinivasan et al., 2021; ASCO Abstract 4555). Inactivating germline mutations in VHL underlie von Hippel_Lindau syndrome, a rare but highly penetrant autosomal dominant syndrome occurring in 1/36,000 live births that predisposes to the development of several types of cancer, including clear cell renal cell carcinomas and pancreatic neuroendocrine tumors, as well as retinal and central nervous system hemangioblastomas (Maher et al., 2011; 21386872, Haddad et al., 2013; 24138046, Richard et al., 2013; 22659535). In the appropriate clinical context, germline testing of VHL is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "ZNF217", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "amplification"}}, "Interpretation": "ZNF217 encodes a candidate oncogene that has likely roles in histone modification and transcriptional repression (Huang et al., 2005; 16203743, Banck et al., 2009; 19242095). ZNF217 amplification has been correlated with protein overexpression in breast carcinoma tumors and cell lines (Collins et al., 1998; 9671742). The role of ZNF217 in promoting tumorigenesis was established in preclinical studies demonstrating that expression of ZNF217 results in the immortalization of both human mammary epithelial cells and ovarian surface epithelial cells in culture (Nonet et al., 2001; 11245413, Li et al., 2007; 17266044). Amplification and/or overexpression of ZNF217 has been reported in breast (Vendrell et al., 2012; 22593193), ovarian (Li et al., 2014; 25031722, Rahman et al., 2012; 22843878), gastric (Yang et al., 2005; 15701848, Shida et al., 2014; 25202062), colon (Rooney et al., 2004; 15476264), prostate (Szczyrba et al., 2012; 22815235), esophageal (Geppert et al., 2014; 24853183), and urothelial carcinomas (Toncheva et al., 2005; 15897688), glioblastoma (Mao et al., 2011; 21483406), and ovarian carcinosarcomas (Schipf et al., 2008; 18193277). Overexpression in these tumors has generally been linked with aggressive tumor behavior and poor clinical prognosis. High levels of ZNF217 expression result in dysregulation of a broad range of genes that may contribute to tumorigenesis (Quinlan et al., 2007; 17572303, Krig et al., 2007; 17259635, Cowger et al., 2007; 17130829), and increased expression or activation of ERBB3 (Krig et al., 2010; 20661224, Vendrell et al., 2012; 22593193), FAK (Vendrell et al., 2012; 22593193), Aurora kinase A (Thollet et al., 2010; 21059223), AKT (Huang et al., 2005; 16203743), and TGF_beta/SMAD signaling (Vendrell et al., 2012; 22593193) has been demonstrated in ZNF217_expressing tumors or cells. There are no available targeted therapies to address genomic alterations in ZNF217. Expression of ZNF217 may predict relapse of estrogen receptor (ER)_positive breast cancer under hormone therapy through its direct interaction with ER_alpha (Nguyen et al., 2014; 24973012, Frietze et al., 2014; 24962896). ZNF217 overexpression has also been associated with resistance to paclitaxel (Thollet et al., 2010; 21059223) and doxorubicin (Huang et al., 2005; 16203743) in breast cancer cell lines. ZNF217 has been suggested as a potential biomarker for treatment with the DNA synthesis inhibitor and AKT inhibitor triciribine in breast cancer based on preclinical findings in cultured cells and xenografts expressing high levels of ZNF217; triciribine treatment also restored sensitivity to doxorubicin in these cells (Littlepage et al., 2012; 22728437).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "MYCN", "Alteration": "amplification", "Title": "A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC_90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non_Hodgkin s Lymphomas", "StudyPhase": "PHASE 1", "Target": "BRD2, BRD3, BRD4, BRDT", "Locations": "Kashiwa (Japan), Meldola (Italy), Napoli, Campania (Italy), Rozzano (MI) (Italy), Villejuif (France), Bordeaux (France), Barcelona (Spain), Madrid (Spain)", "NCTID": "NCT03220347", "Note": "MYCN amplification may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, particularly Aurora kinases A and B, of MDM2, and of BET bromodomain_containing proteins.", "Include": "true"}, {"Gene": "MYCN", "Alteration": "amplification", "Title": "PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration_Resistant Prostate Cancer (mCRPC)", "StudyPhase": "PHASE 1/2", "Target": "BRD4, CYP17, PARP", "Locations": "London (United Kingdom), Wisconsin, Illinois, Michigan, New York, Tennessee, Virginia, South Carolina", "NCTID": "NCT04556617", "Note": "MYCN amplification may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, particularly Aurora kinases A and B, of MDM2, and of BET bromodomain_containing proteins.", "Include": "true"}, {"Gene": "MYCN", "Alteration": "amplification", "Title": "A Study of PLX2853 in Advanced Malignancies.", "StudyPhase": "PHASE 1/2", "Target": "BRD4", "Locations": "Arizona, New York, Texas, Virginia, Florida", "NCTID": "NCT03297424", "Note": "MYCN amplification may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, particularly Aurora kinases A and B, of MDM2, and of BET bromodomain_containing proteins.", "Include": "true"}, {"Gene": "MYCN", "Alteration": "amplification", "Title": "A Study of APG_115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "MDM2, PD_1", "Locations": "Brisbane (Australia), California, Arizona, Missouri, Arkansas, Pennsylvania, New York, Tennessee, Texas", "NCTID": "NCT03611868", "Note": "MYCN amplification may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, particularly Aurora kinases A and B, of MDM2, and of BET bromodomain_containing proteins.", "Include": "true"}, {"Gene": "MYCN", "Alteration": "amplification", "Title": "Alisertib and Pembrolizumab for the Treatment of Patients With Rb_deficient Head and Neck Squamous Cell Cancer", "StudyPhase": "PHASE 1/2", "Target": "Aurora kinase A, PD_1", "Locations": "Texas", "NCTID": "NCT04555837", "Note": "MYCN amplification may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, particularly Aurora kinases A and B, of MDM2, and of BET bromodomain_containing proteins.", "Include": "true"}, {"Gene": "MYCN", "Alteration": "amplification", "Title": "Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors", "StudyPhase": "PHASE 1", "Target": "PARP, CDK1, CDK2, CDK5, CDK9", "Locations": "Massachusetts", "NCTID": "NCT01434316", "Note": "MYCN amplification may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, particularly Aurora kinases A and B, of MDM2, and of BET bromodomain_containing proteins.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "16890795", "FullCitation": "Gollob JA, et al. Semin. Oncol. (2006) pmid: 16890795", "Include": "true"}, {"number": "1", "ReferenceId": "21577205", "FullCitation": "Maurer G, et al. Oncogene (2011) pmid: 21577205", "Include": "true"}, {"number": "2", "ReferenceId": "23550210", "FullCitation": "Gao J, et al. Sci Signal (2013) pmid: 23550210", "Include": "true"}, {"number": "3", "ReferenceId": "24071852", "FullCitation": "Zack TI, et al. Nat. Genet. (2013) pmid: 24071852", "Include": "true"}, {"number": "4", "ReferenceId": "20164920", "FullCitation": "Beroukhim R, et al. Nature (2010) pmid: 20164920", "Include": "true"}, {"number": "5", "ReferenceId": "24569458", "FullCitation": "Imielinski M, et al. J. Clin. Invest. (2014) pmid: 24569458", "Include": "true"}, {"number": "6", "ReferenceId": "12077328", "FullCitation": "Light Y, et al. Mol. Cell. Biol. (2002) pmid: 12077328", "Include": "true"}, {"number": "7", "ReferenceId": "11756411", "FullCitation": "Kubicek M, et al. J. Biol. Chem. (2002) pmid: 11756411", "Include": "true"}, {"number": "8", "ReferenceId": "16407412", "FullCitation": "Balan V, et al. Mol. Biol. Cell (2006) pmid: 16407412", "Include": "true"}, {"number": "9", "ReferenceId": "23529931", "FullCitation": "Deng Y, et al. Blood (2013) pmid: 23529931", "Include": "true"}, {"number": "10", "ReferenceId": "23391722", "FullCitation": "Deng Y, et al. J. Clin. Invest. (2013) pmid: 23391722", "Include": "true"}, {"number": "11", "ReferenceId": "17603483", "FullCitation": "Pandit B, et al. Nat. Genet. (2007) pmid: 17603483", "Include": "true"}, {"number": "12", "ReferenceId": "21339642", "FullCitation": "Wu X, et al. J. Clin. Invest. (2011) pmid: 21339642", "Include": "true"}, {"number": "13", "ReferenceId": "22826437", "FullCitation": "Wu X, et al. Mol. Cell. Biol. (2012) pmid: 22826437", "Include": "true"}, {"number": "14", "ReferenceId": "27273450", "FullCitation": "Atefi M, et al. Sci Rep (2016) pmid: 27273450", "Include": "true"}, {"number": "15", "ReferenceId": "11971957", "FullCitation": "Dhillon AS, et al. Mol. Cell. Biol. (2002) pmid: 11971957", "Include": "true"}, {"number": "16", "ReferenceId": "7760835", "FullCitation": "Michaud NR, et al. Mol. Cell. Biol. (1995) pmid: 7760835", "Include": "true"}, {"number": "17", "ReferenceId": "20679480", "FullCitation": "Molzan M, et al. Mol. Cell. Biol. (2010) pmid: 20679480", "Include": "true"}, {"number": "18", "ReferenceId": "23737487", "FullCitation": "Antony R, et al. Cancer Res. (2013) pmid: 23737487", "Include": "true"}, {"number": "19", "ReferenceId": "17603482", "FullCitation": "Razzaque MA, et al. Nat. Genet. (2007) pmid: 17603482", "Include": "true"}, {"number": "20", "ReferenceId": "20052757", "FullCitation": "Kobayashi T, et al. Hum. Mutat. (2010) pmid: 20052757", "Include": "true"}, {"number": "21", "ReferenceId": "22588877", "FullCitation": "Cerami E, et al. Cancer Discov (2012) pmid: 22588877", "Include": "true"}, {"number": "22", "ReferenceId": "22833462", "FullCitation": "Ren G, et al. Genes Chromosomes Cancer (2012) pmid: 22833462", "Include": "true"}, {"number": "23", "ReferenceId": "30371878", "FullCitation": "Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878", "Include": "true"}, {"number": "24", "ReferenceId": "24223781", "FullCitation": "Chen Y, et al. PLoS ONE (2013) pmid: 24223781", "Include": "true"}, {"number": "25", "ReferenceId": "15666389", "FullCitation": "Mukherjee R, et al. Prostate (2005) pmid: 15666389", "Include": "true"}, {"number": "26", "ReferenceId": "20526349", "FullCitation": "Palanisamy N, et al. Nat. Med. (2010) pmid: 20526349", "Include": "true"}, {"number": "27", "ReferenceId": "30867592", "FullCitation": "Diamond EL, et al. Nature (2019) pmid: 30867592", "Include": "true"}, {"number": "28", "ReferenceId": "26307133", "FullCitation": "Wilson MA, et al. Clin. Cancer Res. (2016) pmid: 26307133", "Include": "true"}, {"number": "29", "ReferenceId": "26981887", "FullCitation": "Lei J, et al. Oncotarget (2016) pmid: 26981887", "Include": "true"}, {"number": "30", "ReferenceId": "16904903", "FullCitation": "Dang CV, et al. Semin. Cancer Biol. (2006) pmid: 16904903", "Include": "true"}, {"number": "31", "ReferenceId": "18003922", "FullCitation": "Liu T, et al. Proc. Natl. Acad. Sci. U.S.A. (2007) pmid: 18003922", "Include": "true"}, {"number": "32", "ReferenceId": "20579941", "FullCitation": "Taylor BS, et al. Cancer Cell (2010) pmid: 20579941", "Include": "true"}, {"number": "33", "ReferenceId": "26544944", "FullCitation": "Cell (2015) pmid: 26544944", "Include": "true"}, {"number": "34", "ReferenceId": "23358695", "FullCitation": "Mosquera JM, et al. Neoplasia (2013) pmid: 23358695", "Include": "true"}, {"number": "35", "ReferenceId": "22389870", "FullCitation": "Beltran H, et al. Cancer Discov (2011) pmid: 22389870", "Include": "true"}, {"number": "36", "ReferenceId": "26855148", "FullCitation": "Beltran H, et al. Nat. Med. (2016) pmid: 26855148", "Include": "true"}, {"number": "37", "ReferenceId": "22430491", "FullCitation": "Horiuchi D, et al. J. Exp. Med. (2012) pmid: 22430491", "Include": "true"}, {"number": "38", "ReferenceId": "17589519", "FullCitation": "Goga A, et al. Nat. Med. (2007) pmid: 17589519", "Include": "true"}, {"number": "39", "ReferenceId": "19525400", "FullCitation": "Molenaar JJ, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19525400", "Include": "true"}, {"number": "40", "ReferenceId": "24317512", "FullCitation": "Delehouz\u00e9 C, et al. Oncogene (2014) pmid: 24317512", "Include": "true"}, {"number": "41", "ReferenceId": "26202950", "FullCitation": "Dolman ME, et al. Clin. Cancer Res. (2015) pmid: 26202950", "Include": "true"}, {"number": "42", "ReferenceId": "23430699", "FullCitation": "Puissant A, et al. Cancer Discov (2013) pmid: 23430699", "Include": "true"}, {"number": "43", "ReferenceId": "25535366", "FullCitation": "Baratta MG, et al. Proc. Natl. Acad. Sci. U.S.A. (2015) pmid: 25535366", "Include": "true"}, {"number": "44", "ReferenceId": "24796395", "FullCitation": "Venkataraman S, et al. Oncotarget (2014) pmid: 24796395", "Include": "true"}, {"number": "45", "ReferenceId": "24009722", "FullCitation": "Wyce A, et al. PLoS ONE (2013) pmid: 24009722", "Include": "true"}, {"number": "46", "ReferenceId": "26631615", "FullCitation": "Henssen A, et al. Clin. Cancer Res. (2016) pmid: 26631615", "Include": "true"}, {"number": "47", "ReferenceId": "19111882", "FullCitation": "Otto T, et al. Cancer Cell (2009) pmid: 19111882", "Include": "true"}, {"number": "48", "ReferenceId": "22222631", "FullCitation": "Hook KE, et al. Mol. Cancer Ther. (2012) pmid: 22222631", "Include": "true"}, {"number": "49", "ReferenceId": "23792191", "FullCitation": "Brockmann M, et al. Cancer Cell (2013) pmid: 23792191", "Include": "true"}, {"number": "50", "ReferenceId": "21885865", "FullCitation": "Faisal A, et al. Mol. Cancer Ther. (2011) pmid: 21885865", "Include": "true"}, {"number": "51", "ReferenceId": "25533335", "FullCitation": "Hill RM, et al. Cancer Cell (2015) pmid: 25533335", "Include": "true"}, {"number": "52", "ReferenceId": "26859456", "FullCitation": "Ham J, et al. Cancer Cell (2016) pmid: 26859456", "Include": "true"}, {"number": "53", "ReferenceId": "25175806", "FullCitation": "Gustafson WC, et al. Cancer Cell (2014) pmid: 25175806", "Include": "true"}, {"number": "54", "ReferenceId": "25370467", "FullCitation": "Moreno L, et al. Clin. Cancer Res. (2015) pmid: 25370467", "Include": "true"}, {"number": "55", "ReferenceId": "26884555", "FullCitation": "DuBois SG, et al. J. Clin. Oncol. (2016) pmid: 26884555", "Include": "true"}, {"number": "56", "ReferenceId": "19649205", "FullCitation": "Chen Z, et al. Neoplasia (2009) pmid: 19649205", "Include": "true"}, {"number": "57", "ReferenceId": "19903807", "FullCitation": "Van Maerken T, et al. J. Natl. Cancer Inst. (2009) pmid: 19903807", "Include": "true"}, {"number": "58", "ReferenceId": "21862876", "FullCitation": "He J, et al. Cell Cycle (2011) pmid: 21862876", "Include": "true"}, {"number": "59", "ReferenceId": "21173028", "FullCitation": "Petroni M, et al. Mol. Cancer Res. (2011) pmid: 21173028", "Include": "true"}, {"number": "60", "ReferenceId": "21725357", "FullCitation": "Gamble LD, et al. Oncogene (2012) pmid: 21725357", "Include": "true"}, {"number": "61", "ReferenceId": "22174364", "FullCitation": "Singhal J, et al. Cancer Prev Res (Phila) (2012) pmid: 22174364", "Include": "true"}, {"number": "62", "ReferenceId": "22065083", "FullCitation": "Tonelli R, et al. Clin. Cancer Res. (2012) pmid: 22065083", "Include": "true"}, {"number": "63", "ReferenceId": "21763962", "FullCitation": "Li L, et al. Hematol. Oncol. Clin. North Am. (2011) pmid: 21763962", "Include": "true"}, {"number": "64", "ReferenceId": "18498744", "FullCitation": "Kaelin WG, et al. Mol. Cell (2008) pmid: 18498744", "Include": "true"}, {"number": "65", "ReferenceId": "8855222", "FullCitation": "Gnarra JR, et al. Proc. Natl. Acad. Sci. U.S.A. (1996) pmid: 8855222", "Include": "true"}, {"number": "66", "ReferenceId": "23606570", "FullCitation": "Albers J, et al. EMBO Mol Med (2013) pmid: 23606570", "Include": "true"}, {"number": "67", "ReferenceId": "22462637", "FullCitation": "Asakawa T, et al. BMC Med. Genet. (2012) pmid: 22462637", "Include": "true"}, {"number": "68", "ReferenceId": "16488999", "FullCitation": "Banks RE, et al. Cancer Res. (2006) pmid: 16488999", "Include": "true"}, {"number": "69", "ReferenceId": "21454469", "FullCitation": "Bond J, et al. Blood (2011) pmid: 21454469", "Include": "true"}, {"number": "70", "ReferenceId": "11331613", "FullCitation": "Clifford SC, et al. Hum. Mol. Genet. (2001) pmid: 11331613", "Include": "true"}, {"number": "71", "ReferenceId": "10823831", "FullCitation": "Cockman ME, et al. J. Biol. Chem. (2000) pmid: 10823831", "Include": "true"}, {"number": "72", "ReferenceId": "14556007", "FullCitation": "Corn PG, et al. Nat. Genet. (2003) pmid: 14556007", "Include": "true"}, {"number": "73", "ReferenceId": "22799452", "FullCitation": "Dandanell M, et al. BMC Med. Genet. (2012) pmid: 22799452", "Include": "true"}, {"number": "74", "ReferenceId": "10635329", "FullCitation": "Feldman DE, et al. Mol. Cell (1999) pmid: 10635329", "Include": "true"}, {"number": "75", "ReferenceId": "14636579", "FullCitation": "Feldman DE, et al. Mol. Cell (2003) pmid: 14636579", "Include": "true"}, {"number": "76", "ReferenceId": "11865071", "FullCitation": "Hansen WJ, et al. Mol. Cell. Biol. (2002) pmid: 11865071", "Include": "true"}, {"number": "77", "ReferenceId": "11331612", "FullCitation": "Hoffman MA, et al. Hum. Mol. Genet. (2001) pmid: 11331612", "Include": "true"}, {"number": "78", "ReferenceId": "17967880", "FullCitation": "Khacho M, et al. Mol. Cell. Biol. (2008) pmid: 17967880", "Include": "true"}, {"number": "79", "ReferenceId": "7660130", "FullCitation": "Kibel A, et al. Science (1995) pmid: 7660130", "Include": "true"}, {"number": "80", "ReferenceId": "16261165", "FullCitation": "Knauth K, et al. Oncogene (2006) pmid: 16261165", "Include": "true"}, {"number": "81", "ReferenceId": "14691445", "FullCitation": "Lewis MD, et al. Oncogene (2004) pmid: 14691445", "Include": "true"}, {"number": "82", "ReferenceId": "11739384", "FullCitation": "Li Z, et al. J. Biol. Chem. (2002) pmid: 11739384", "Include": "true"}, {"number": "83", "ReferenceId": "12056827", "FullCitation": "Li Z, et al. Biochem. Biophys. Res. Commun. (2002) pmid: 12056827", "Include": "true"}, {"number": "84", "ReferenceId": "19798438", "FullCitation": "Liu J, et al. PLoS Comput. Biol. (2009) pmid: 19798438", "Include": "true"}, {"number": "85", "ReferenceId": "23298237", "FullCitation": "Losonczy G, et al. BMC Med. Genet. (2013) pmid: 23298237", "Include": "true"}, {"number": "86", "ReferenceId": "8730290", "FullCitation": "Maher ER, et al. J. Med. Genet. (1996) pmid: 8730290", "Include": "true"}, {"number": "87", "ReferenceId": "15935760", "FullCitation": "McClellan AJ, et al. Cell (2005) pmid: 15935760", "Include": "true"}, {"number": "88", "ReferenceId": "19073890", "FullCitation": "Metzger MB, et al. Mol. Biol. Cell (2009) pmid: 19073890", "Include": "true"}, {"number": "89", "ReferenceId": "15611064", "FullCitation": "Miller F, et al. J. Biol. Chem. (2005) pmid: 15611064", "Include": "true"}, {"number": "90", "ReferenceId": "22022277", "FullCitation": "Moore LE, et al. PLoS Genet. (2011) pmid: 22022277", "Include": "true"}, {"number": "91", "ReferenceId": "7563486", "FullCitation": "Neumann HP, et al. JAMA (1995) pmid: 7563486", "Include": "true"}, {"number": "92", "ReferenceId": "10587522", "FullCitation": "Ohh M, et al. J. Clin. Invest. (1999) pmid: 10587522", "Include": "true"}, {"number": "93", "ReferenceId": "10878807", "FullCitation": "Ohh M, et al. Nat. Cell Biol. (2000) pmid: 10878807", "Include": "true"}, {"number": "94", "ReferenceId": "9829912", "FullCitation": "Olschwang S, et al. Hum. Mutat. (1998) pmid: 9829912", "Include": "true"}, {"number": "95", "ReferenceId": "18416845", "FullCitation": "Patocs A, et al. BMC Med. Genet. (2008) pmid: 18416845", "Include": "true"}, {"number": "96", "ReferenceId": "21715564", "FullCitation": "Rechsteiner MP, et al. Cancer Res. (2011) pmid: 21715564", "Include": "true"}, {"number": "97", "ReferenceId": "14987375", "FullCitation": "Expert Rev Mol Med (2001) pmid: 14987375", "Include": "true"}, {"number": "98", "ReferenceId": "8772572", "FullCitation": "Ritter MM, et al. J. Clin. Endocrinol. Metab. (1996) pmid: 8772572", "Include": "true"}, {"number": "99", "ReferenceId": "10900011", "FullCitation": "Schoenfeld AR, et al. Proc. Natl. Acad. Sci. U.S.A. (2000) pmid: 10900011", "Include": "true"}, {"number": "100", "ReferenceId": "23840444", "FullCitation": "Shmueli MD, et al. PLoS ONE (2013) pmid: 23840444", "Include": "true"}, {"number": "101", "ReferenceId": "21362373", "FullCitation": "Siu WK, et al. Chin. Med. J. (2011) pmid: 21362373", "Include": "true"}, {"number": "102", "ReferenceId": "12414898", "FullCitation": "Weirich G, et al. J. Clin. Endocrinol. Metab. (2002) pmid: 12414898", "Include": "true"}, {"number": "103", "ReferenceId": "8956040", "FullCitation": "Zbar B, et al. Hum. Mutat. (1996) pmid: 8956040", "Include": "true"}, {"number": "104", "ReferenceId": "14973063", "FullCitation": "Zhou MI, et al. Cancer Res. (2004) pmid: 14973063", "Include": "true"}, {"number": "105", "ReferenceId": "22610119", "FullCitation": "Barbieri CE, et al. Nat. Genet. (2012) pmid: 22610119", "Include": "true"}, {"number": "106", "ReferenceId": "23622249", "FullCitation": "Baca SC, et al. Cell (2013) pmid: 23622249", "Include": "true"}, {"number": "107", "ReferenceId": "19017755", "FullCitation": "Jimenez C, et al. J. Clin. Endocrinol. Metab. (2009) pmid: 19017755", "Include": "true"}, {"number": "108", "ReferenceId": "24454008", "FullCitation": "Kim HC, et al. Cancer Res Treat (2013) pmid: 24454008", "Include": "true"}, {"number": "109", "ReferenceId": "26881543", "FullCitation": "J Cancer Res Ther () pmid: 26881543", "Include": "true"}, {"number": "110", "ReferenceId": "26812297", "FullCitation": "Babinska A, et al. Neuro Endocrinol. Lett. (2015) pmid: 26812297", "Include": "true"}, {"number": "111", "ReferenceId": "26984080", "FullCitation": "Kobayashi A, et al. Intern. Med. (2016) pmid: 26984080", "Include": "true"}, {"number": "112", "ReferenceId": "22105611", "FullCitation": "Jonasch E, et al. Ann. Oncol. (2011) pmid: 22105611", "Include": "true"}, {"number": "113", "ReferenceId": "25391617", "FullCitation": "Roma A, et al. Fam. Cancer (2015) pmid: 25391617", "Include": "true"}, {"number": "114", "ReferenceId": "16827904", "FullCitation": "Rini BI, et al. BJU Int. (2006) pmid: 16827904", "Include": "true"}, {"number": "115", "ReferenceId": "18635227", "FullCitation": "Choueiri TK, et al. J. Urol. (2008) pmid: 18635227", "Include": "true"}, {"number": "116", "ReferenceId": "25100134", "FullCitation": "Motzer RJ, et al. Cancer Chemother. Pharmacol. (2014) pmid: 25100134", "Include": "true"}, {"number": "117", "ReferenceId": "17956710", "FullCitation": "Cho D, et al. Clin Genitourin Cancer (2007) pmid: 17956710", "Include": "true"}, {"number": "118", "ReferenceId": "23881929", "FullCitation": "Choueiri TK, et al. Clin. Cancer Res. (2013) pmid: 23881929", "Include": "true"}, {"number": "119", "ReferenceId": "21386872", "FullCitation": "Maher ER, et al. Eur. J. Hum. Genet. (2011) pmid: 21386872", "Include": "true"}, {"number": "120", "ReferenceId": "24138046", "FullCitation": "Haddad NM, et al. Semin Ophthalmol () pmid: 24138046", "Include": "true"}, {"number": "121", "ReferenceId": "22659535", "FullCitation": "Richard S, et al. Semin. Cancer Biol. (2013) pmid: 22659535", "Include": "true"}, {"number": "122", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "123", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "124", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "125", "ReferenceId": "9823339", "FullCitation": "Boland CR, et al. Cancer Res. (1998) pmid: 9823339", "Include": "true"}, {"number": "126", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "127", "ReferenceId": "20420947", "FullCitation": "Boland CR, et al. Gastroenterology (2010) pmid: 20420947", "Include": "true"}, {"number": "128", "ReferenceId": "25255306", "FullCitation": "Pritchard CC, et al. Nat Commun (2014) pmid: 25255306", "Include": "true"}, {"number": "129", "ReferenceId": "18336598", "FullCitation": "Schwarzenbach H, et al. BJU Int. (2008) pmid: 18336598", "Include": "true"}, {"number": "130", "ReferenceId": "7493915", "FullCitation": "Suzuki H, et al. Jpn. J. Cancer Res. (1995) pmid: 7493915", "Include": "true"}, {"number": "131", "ReferenceId": "27013479", "FullCitation": "Dominguez_Valentin M, et al. BMC Urol (2016) pmid: 27013479", "Include": "true"}, {"number": "132", "ReferenceId": "25117503", "FullCitation": "Rosty C, et al. Fam. Cancer (2014) pmid: 25117503", "Include": "true"}, {"number": "133", "ReferenceId": "11251526", "FullCitation": "Ahman AK, et al. BJU Int. (2001) pmid: 11251526", "Include": "true"}, {"number": "134", "ReferenceId": "30382943", "FullCitation": "Rodrigues DN, et al. J. Clin. Invest. (2018) pmid: 30382943", "Include": "true"}, {"number": "135", "ReferenceId": "25392179", "FullCitation": "Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179", "Include": "true"}, {"number": "136", "ReferenceId": "26140250", "FullCitation": "Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250", "Include": "true"}, {"number": "137", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "138", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "139", "ReferenceId": "9860993", "FullCitation": "Hayward BE, et al. Proc. Natl. Acad. Sci. U.S.A. (1998) pmid: 9860993", "Include": "true"}, {"number": "140", "ReferenceId": "2549064", "FullCitation": "Masters SB, et al. J. Biol. Chem. (1989) pmid: 2549064", "Include": "true"}, {"number": "141", "ReferenceId": "2549065", "FullCitation": "Graziano MP, et al. J. Biol. Chem. (1989) pmid: 2549065", "Include": "true"}, {"number": "142", "ReferenceId": "11322485", "FullCitation": "Jang IS, et al. Exp. Mol. Med. (2001) pmid: 11322485", "Include": "true"}, {"number": "143", "ReferenceId": "2549426", "FullCitation": "Landis CA, et al. Nature (1989) pmid: 2549426", "Include": "true"}, {"number": "144", "ReferenceId": "23288949", "FullCitation": "Tobar_Rubin R, et al. J. Mol. Endocrinol. (2013) pmid: 23288949", "Include": "true"}, {"number": "145", "ReferenceId": "20887824", "FullCitation": "Mariot V, et al. Bone (2011) pmid: 20887824", "Include": "true"}, {"number": "146", "ReferenceId": "1944469", "FullCitation": "Weinstein LS, et al. N. Engl. J. Med. (1991) pmid: 1944469", "Include": "true"}, {"number": "147", "ReferenceId": "12970318", "FullCitation": "Collins MT, et al. J. Clin. Endocrinol. Metab. (2003) pmid: 12970318", "Include": "true"}, {"number": "148", "ReferenceId": "21835143", "FullCitation": "Nault JC, et al. J. Hepatol. (2012) pmid: 21835143", "Include": "true"}, {"number": "149", "ReferenceId": "22355676", "FullCitation": "Furukawa T, et al. Sci Rep (2011) pmid: 22355676", "Include": "true"}, {"number": "150", "ReferenceId": "21775669", "FullCitation": "Wu J, et al. Sci Transl Med (2011) pmid: 21775669", "Include": "true"}, {"number": "151", "ReferenceId": "23403822", "FullCitation": "Nishikawa G, et al. Br. J. Cancer (2013) pmid: 23403822", "Include": "true"}, {"number": "152", "ReferenceId": "24925222", "FullCitation": "Singhi AD, et al. Hum. Pathol. (2014) pmid: 24925222", "Include": "true"}, {"number": "153", "ReferenceId": "21720365", "FullCitation": "Nature (2011) pmid: 21720365", "Include": "true"}, {"number": "154", "ReferenceId": "20668451", "FullCitation": "Kan Z, et al. Nature (2010) pmid: 20668451", "Include": "true"}, {"number": "155", "ReferenceId": "20537689", "FullCitation": "Tominaga E, et al. Gynecol. Oncol. (2010) pmid: 20537689", "Include": "true"}, {"number": "156", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "157", "ReferenceId": "25079317", "FullCitation": "Nature (2014) pmid: 25079317", "Include": "true"}, {"number": "158", "ReferenceId": "25079552", "FullCitation": "Nature (2014) pmid: 25079552", "Include": "true"}, {"number": "159", "ReferenceId": "23000897", "FullCitation": "Nature (2012) pmid: 23000897", "Include": "true"}, {"number": "160", "ReferenceId": "25855536", "FullCitation": "Witkiewicz AK, et al. Nat Commun (2015) pmid: 25855536", "Include": "true"}, {"number": "161", "ReferenceId": "20601955", "FullCitation": "Barretina J, et al. Nat. Genet. (2010) pmid: 20601955", "Include": "true"}, {"number": "162", "ReferenceId": "24434212", "FullCitation": "Lohr JG, et al. Cancer Cell (2014) pmid: 24434212", "Include": "true"}, {"number": "163", "ReferenceId": "21430775", "FullCitation": "Chapman MA, et al. Nature (2011) pmid: 21430775", "Include": "true"}, {"number": "164", "ReferenceId": "21357941", "FullCitation": "Zacharin M, et al. J. Med. Genet. (2011) pmid: 21357941", "Include": "true"}, {"number": "165", "ReferenceId": "20027678", "FullCitation": "Alakus H, et al. World J. Gastroenterol. (2009) pmid: 20027678", "Include": "true"}, {"number": "166", "ReferenceId": "28868010", "FullCitation": "Ang C, et al. Case Rep Oncol () pmid: 28868010", "Include": "true"}, {"number": "167", "ReferenceId": "31740567", "FullCitation": "Saunders IM, et al. Oncologist (2019) pmid: 31740567", "Include": "true"}, {"number": "168", "ReferenceId": "12169433", "FullCitation": "Am. J. Physiol. Endocrinol. Metab. (2002) pmid: 12169433", "Include": "true"}, {"number": "169", "ReferenceId": "23594372", "FullCitation": "Day E, et al. Int J Exp Pathol (2013) pmid: 23594372", "Include": "true"}, {"number": "170", "ReferenceId": "25527633", "FullCitation": "Huang F, et al. Mol. Cancer Ther. (2015) pmid: 25527633", "Include": "true"}, {"number": "171", "ReferenceId": "26000489", "FullCitation": "Robinson D, et al. Cell (2015) pmid: 26000489", "Include": "true"}, {"number": "172", "ReferenceId": "26928463", "FullCitation": "Kumar A, et al. Nat. Med. (2016) pmid: 26928463", "Include": "true"}, {"number": "173", "ReferenceId": "24476821", "FullCitation": "Nature (2014) pmid: 24476821", "Include": "true"}, {"number": "174", "ReferenceId": "24798001", "FullCitation": "Ahn SM, et al. Hepatology (2014) pmid: 24798001", "Include": "true"}, {"number": "175", "ReferenceId": "22287730", "FullCitation": "Shaw CM, et al. Anticancer Res. (2012) pmid: 22287730", "Include": "true"}, {"number": "176", "ReferenceId": "26991655", "FullCitation": "Becker MA, et al. PLoS ONE (2016) pmid: 26991655", "Include": "true"}, {"number": "177", "ReferenceId": "19261680", "FullCitation": "de Blaqui\u00e8re GE, et al. Endocr. Relat. Cancer (2009) pmid: 19261680", "Include": "true"}, {"number": "178", "ReferenceId": "17361103", "FullCitation": "Gibson SL, et al. Cell Cycle (2007) pmid: 17361103", "Include": "true"}, {"number": "179", "ReferenceId": "19243297", "FullCitation": "Future Oncol (2009) pmid: 19243297", "Include": "true"}, {"number": "180", "ReferenceId": "23562473", "FullCitation": "Porter HA, et al. Cancer Lett. (2013) pmid: 23562473", "Include": "true"}, {"number": "181", "ReferenceId": "19671761", "FullCitation": "Zha J, et al. Mol. Cancer Ther. (2009) pmid: 19671761", "Include": "true"}, {"number": "182", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "183", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "184", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "185", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "186", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "187", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "188", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "189", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "190", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "191", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "192", "ReferenceId": "28835386", "FullCitation": "Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386", "Include": "true"}, {"number": "193", "ReferenceId": "32919526", "FullCitation": "Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526", "Include": "true"}, {"number": "194", "ReferenceId": "31405947", "FullCitation": "Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947", "Include": "true"}, {"number": "195", "ReferenceId": "28420421", "FullCitation": "Chalmers ZR, et al. Genome Med (2017) pmid: 28420421", "Include": "true"}, {"number": "196", "ReferenceId": "23770567", "FullCitation": "Lawrence MS, et al. Nature (2013) pmid: 23770567", "Include": "true"}, {"number": "197", "ReferenceId": "23945592", "FullCitation": "Alexandrov LB, et al. Nature (2013) pmid: 23945592", "Include": "true"}, {"number": "198", "ReferenceId": "22722839", "FullCitation": "Grasso CS, et al. Nature (2012) pmid: 22722839", "Include": "true"}, {"number": "199", "ReferenceId": "25830880", "FullCitation": "Gundem G, et al. Nature (2015) pmid: 25830880", "Include": "true"}, {"number": "200", "ReferenceId": "30643254", "FullCitation": "Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254", "Include": "true"}, {"number": "201", "ReferenceId": "30309915", "FullCitation": "Cristescu R, et al. Science (2018) pmid: 30309915", "Include": "true"}, {"number": "202", "ReferenceId": "30785829", "FullCitation": "Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829", "Include": "true"}, {"number": "203", "ReferenceId": "29658845", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845", "Include": "true"}, {"number": "204", "ReferenceId": "29657128", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128", "Include": "true"}, {"number": "205", "ReferenceId": "29731394", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394", "Include": "true"}, {"number": "206", "ReferenceId": "33558721", "FullCitation": "Rozeman EA, et al. Nat Med (2021) pmid: 33558721", "Include": "true"}, {"number": "207", "ReferenceId": "32916128", "FullCitation": "Sharma P, et al. Cancer Cell (2020) pmid: 32916128", "Include": "true"}, {"number": "208", "ReferenceId": "9585501", "FullCitation": "Wang C, et al. Genes Dev. (1998) pmid: 9585501", "Include": "true"}, {"number": "209", "ReferenceId": "22158541", "FullCitation": "Quesada V, et al. Nat. Genet. (2011) pmid: 22158541", "Include": "true"}, {"number": "210", "ReferenceId": "22150006", "FullCitation": "Wang L, et al. N. Engl. J. Med. (2011) pmid: 22150006", "Include": "true"}, {"number": "211", "ReferenceId": "22826563", "FullCitation": "Visconte V, et al. Blood (2012) pmid: 22826563", "Include": "true"}, {"number": "212", "ReferenceId": "22200771", "FullCitation": "Hahn CN, et al. Nat. Genet. (2011) pmid: 22200771", "Include": "true"}, {"number": "213", "ReferenceId": "22039264", "FullCitation": "Rossi D, et al. Blood (2011) pmid: 22039264", "Include": "true"}, {"number": "214", "ReferenceId": "23390883", "FullCitation": "Yang J, et al. Genet Test Mol Biomarkers (2013) pmid: 23390883", "Include": "true"}, {"number": "215", "ReferenceId": "22096241", "FullCitation": "Patnaik MM, et al. Blood (2012) pmid: 22096241", "Include": "true"}, {"number": "216", "ReferenceId": "25424858", "FullCitation": "Maguire SL, et al. J. Pathol. (2015) pmid: 25424858", "Include": "true"}, {"number": "217", "ReferenceId": "23568491", "FullCitation": "Wan Y, et al. Blood (2013) pmid: 23568491", "Include": "true"}, {"number": "218", "ReferenceId": "24434863", "FullCitation": "Gentien D, et al. Leukemia (2014) pmid: 24434863", "Include": "true"}, {"number": "219", "ReferenceId": "2576898", "FullCitation": "Schmidt M, et al. Diabetes Res. (1989) pmid: 2576898", "Include": "true"}, {"number": "220", "ReferenceId": "26565915", "FullCitation": "Darman RB, et al. Cell Rep (2015) pmid: 26565915", "Include": "true"}, {"number": "221", "ReferenceId": "26842708", "FullCitation": "Alsafadi S, et al. Nat Commun (2016) pmid: 26842708", "Include": "true"}, {"number": "222", "ReferenceId": "23778141", "FullCitation": "Stephens PJ, et al. J. Clin. Invest. (2013) pmid: 23778141", "Include": "true"}, {"number": "223", "ReferenceId": "26095796", "FullCitation": "Martelotto LG, et al. J. Pathol. (2015) pmid: 26095796", "Include": "true"}, {"number": "224", "ReferenceId": "23103869", "FullCitation": "Biankin AV, et al. Nature (2012) pmid: 23103869", "Include": "true"}, {"number": "225", "ReferenceId": "25326804", "FullCitation": "Xie M, et al. Nat. Med. (2014) pmid: 25326804", "Include": "true"}, {"number": "226", "ReferenceId": "22722202", "FullCitation": "Banerji S, et al. Nature (2012) pmid: 22722202", "Include": "true"}, {"number": "227", "ReferenceId": "22722193", "FullCitation": "Ellis MJ, et al. Nature (2012) pmid: 22722193", "Include": "true"}, {"number": "228", "ReferenceId": "29383138", "FullCitation": "Fu X, et al. Oncotarget (2017) pmid: 29383138", "Include": "true"}, {"number": "229", "ReferenceId": "31206197", "FullCitation": "Nault JC, et al. Hepatology (2020) pmid: 31206197", "Include": "true"}, {"number": "230", "ReferenceId": "23861464", "FullCitation": "Furney SJ, et al. Cancer Discov (2013) pmid: 23861464", "Include": "true"}, {"number": "231", "ReferenceId": "27622333", "FullCitation": "Obeng EA, et al. Cancer Cell (2016) pmid: 27622333", "Include": "true"}, {"number": "232", "ReferenceId": "27135740", "FullCitation": "Lee SC, et al. Nat. Med. (2016) pmid: 27135740", "Include": "true"}, {"number": "233", "ReferenceId": "27836865", "FullCitation": "Yoshimi A, et al. Clin. Cancer Res. (2017) pmid: 27836865", "Include": "true"}, {"number": "234", "ReferenceId": "27603132", "FullCitation": "Lee SC, et al. Nat. Med. (2016) pmid: 27603132", "Include": "true"}, {"number": "235", "ReferenceId": "32076118", "FullCitation": "Singh S, et al. Leukemia (2020) pmid: 32076118", "Include": "true"}, {"number": "236", "ReferenceId": "25426837", "FullCitation": "Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837", "Include": "true"}, {"number": "237", "ReferenceId": "25426838", "FullCitation": "Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838", "Include": "true"}, {"number": "238", "ReferenceId": "28669404", "FullCitation": "Acuna_Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404", "Include": "true"}, {"number": "239", "ReferenceId": "29678827", "FullCitation": "Severson EA, et al. Blood (2018) pmid: 29678827", "Include": "true"}, {"number": "240", "ReferenceId": "29420212", "FullCitation": "Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212", "Include": "true"}, {"number": "241", "ReferenceId": "30504320", "FullCitation": "Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320", "Include": "true"}, {"number": "242", "ReferenceId": "32269342", "FullCitation": "Chabon JJ, et al. Nature (2020) pmid: 32269342", "Include": "true"}, {"number": "243", "ReferenceId": "31768066", "FullCitation": "Razavi P, et al. Nat. Med. (2019) pmid: 31768066", "Include": "true"}, {"number": "244", "ReferenceId": "22124843", "FullCitation": "Niraula S, et al. Horm Cancer (2012) pmid: 22124843", "Include": "true"}, {"number": "245", "ReferenceId": "24481405", "FullCitation": "Merson S, et al. Br J Cancer (2014) pmid: 24481405", "Include": "true"}, {"number": "246", "ReferenceId": "7795646", "FullCitation": "Visakorpi T, et al. Nat. Genet. (1995) pmid: 7795646", "Include": "true"}, {"number": "247", "ReferenceId": "9000575", "FullCitation": "Koivisto P, et al. Cancer Res. (1997) pmid: 9000575", "Include": "true"}, {"number": "248", "ReferenceId": "10029066", "FullCitation": "Bubendorf L, et al. Cancer Res. (1999) pmid: 10029066", "Include": "true"}, {"number": "249", "ReferenceId": "11325816", "FullCitation": "Linja MJ, et al. Cancer Res (2001) pmid: 11325816", "Include": "true"}, {"number": "250", "ReferenceId": "11061898", "FullCitation": "Palmberg C, et al. J. Urol. (2000) pmid: 11061898", "Include": "true"}, {"number": "251", "ReferenceId": "17217995", "FullCitation": "Haapala K, et al. Hum. Pathol. (2007) pmid: 17217995", "Include": "true"}, {"number": "252", "ReferenceId": "23806491", "FullCitation": "Schrecengost R, et al. Semin. Oncol. (2013) pmid: 23806491", "Include": "true"}, {"number": "253", "ReferenceId": "23565753", "FullCitation": "Schmidt LJ, et al. Curr Drug Targets (2013) pmid: 23565753", "Include": "true"}, {"number": "254", "ReferenceId": "25712683", "FullCitation": "Azad AA, et al. Clin. Cancer Res. (2015) pmid: 25712683", "Include": "true"}, {"number": "255", "ReferenceId": "22245783", "FullCitation": "Waltering KK, et al. Mol Cell Endocrinol (2012) pmid: 22245783", "Include": "true"}, {"number": "256", "ReferenceId": "29574703", "FullCitation": "Belic J, et al. Int J Cancer (2018) pmid: 29574703", "Include": "true"}, {"number": "257", "ReferenceId": "27148695", "FullCitation": "Wyatt AW, et al. JAMA Oncol (2016) pmid: 27148695", "Include": "true"}, {"number": "258", "ReferenceId": "30620391", "FullCitation": "Sonpavde G, et al. Cancer (2019) pmid: 30620391", "Include": "true"}, {"number": "259", "ReferenceId": "19339269", "FullCitation": "Attard G, et al. Cancer Res (2009) pmid: 19339269", "Include": "true"}, {"number": "260", "ReferenceId": "32268276", "FullCitation": "Kohli M, et al. EBioMedicine (2020) pmid: 32268276", "Include": "true"}, {"number": "261", "ReferenceId": "33836265", "FullCitation": "Annala M, et al. Ann Oncol (2021) pmid: 33836265", "Include": "true"}, {"number": "262", "ReferenceId": "33675416", "FullCitation": "Kubota Y, et al. World J Urol (2021) pmid: 33675416", "Include": "true"}, {"number": "263", "ReferenceId": "29858592", "FullCitation": "Kohli M, et al. Prostate Cancer Prostatic Dis (2018) pmid: 29858592", "Include": "true"}, {"number": "264", "ReferenceId": "30773204", "FullCitation": "Conteduca V, et al. Eur Urol (2019) pmid: 30773204", "Include": "true"}, {"number": "265", "ReferenceId": "34083234", "FullCitation": "Annala M, et al. Clin Cancer Res (2021) pmid: 34083234", "Include": "true"}, {"number": "266", "ReferenceId": "33500577", "FullCitation": "Del Re M, et al. Prostate Cancer Prostatic Dis (2021) pmid: 33500577", "Include": "true"}, {"number": "267", "ReferenceId": "28472366", "FullCitation": "Conteduca V, et al. Ann Oncol (2017) pmid: 28472366", "Include": "true"}, {"number": "268", "ReferenceId": "26537258", "FullCitation": "Romanel A, et al. Sci Transl Med (2015) pmid: 26537258", "Include": "true"}, {"number": "269", "ReferenceId": "27191887", "FullCitation": "Salvi S, et al. Oncotarget (2016) pmid: 27191887", "Include": "true"}, {"number": "270", "ReferenceId": "29367197", "FullCitation": "Annala M, et al. Cancer Discov (2018) pmid: 29367197", "Include": "true"}, {"number": "271", "ReferenceId": "23819055", "FullCitation": "Patel JC, et al. Prostate Cancer (2013) pmid: 23819055", "Include": "true"}, {"number": "272", "ReferenceId": "23724747", "FullCitation": "Chowdhury S, et al. Practitioner (2013) pmid: 23724747", "Include": "true"}, {"number": "273", "ReferenceId": "6135909", "FullCitation": "Ahmed SR, et al. Lancet (1983) pmid: 6135909", "Include": "true"}, {"number": "274", "ReferenceId": "29420164", "FullCitation": "Smith MR, et al. N. Engl. J. Med. (2018) pmid: 29420164", "Include": "true"}, {"number": "275", "ReferenceId": "30763142", "FullCitation": "Fizazi K, et al. N. Engl. J. Med. (2019) pmid: 30763142", "Include": "true"}, {"number": "276", "ReferenceId": "24974051", "FullCitation": "Fizazi K, et al. Lancet Oncol. (2014) pmid: 24974051", "Include": "true"}, {"number": "277", "ReferenceId": "22174412", "FullCitation": "Soifer HS, et al. J. Biol. Chem. (2012) pmid: 22174412", "Include": "true"}, {"number": "278", "ReferenceId": "21808270", "FullCitation": "Nat Rev Clin Oncol (2011) pmid: 21808270", "Include": "true"}, {"number": "279", "ReferenceId": "32278840", "FullCitation": "Hird AE, et al. Clin Genitourin Cancer (2020) pmid: 32278840", "Include": "true"}, {"number": "280", "ReferenceId": "23863692", "FullCitation": "van der Steen T, et al. Int J Mol Sci (2013) pmid: 23863692", "Include": "true"}, {"number": "281", "ReferenceId": "24019458", "FullCitation": "Lee E, et al. Proc. Natl. Acad. Sci. U.S.A. (2013) pmid: 24019458", "Include": "true"}, {"number": "282", "ReferenceId": "23989930", "FullCitation": "Gowda PS, et al. Mol. Cancer Res. (2013) pmid: 23989930", "Include": "true"}, {"number": "283", "ReferenceId": "23851510", "FullCitation": "Liu LL, et al. Oncogene (2014) pmid: 23851510", "Include": "true"}, {"number": "284", "ReferenceId": "27487144", "FullCitation": "Wadosky KM, et al. Oncotarget (2016) pmid: 27487144", "Include": "true"}, {"number": "285", "ReferenceId": "24203954", "FullCitation": "Bartek J, et al. Cancer Discov (2013) pmid: 24203954", "Include": "true"}, {"number": "286", "ReferenceId": "24200698", "FullCitation": "van Soest RJ, et al. Eur. J. Cancer (2013) pmid: 24200698", "Include": "true"}, {"number": "287", "ReferenceId": "27262168", "FullCitation": "Scher HI, et al. JAMA Oncol (2016) pmid: 27262168", "Include": "true"}, {"number": "288", "ReferenceId": "26181238", "FullCitation": "Antonarakis ES, et al. JAMA Oncol (2015) pmid: 26181238", "Include": "true"}, {"number": "289", "ReferenceId": "23861347", "FullCitation": "Loddick SA, et al. Mol. Cancer Ther. (2013) pmid: 23861347", "Include": "true"}, {"number": "290", "ReferenceId": "24002508", "FullCitation": "Rathkopf DE, et al. J. Clin. Oncol. (2013) pmid: 24002508", "Include": "true"}, {"number": "291", "ReferenceId": "27160947", "FullCitation": "Smith MR, et al. Eur. Urol. (2016) pmid: 27160947", "Include": "true"}, {"number": "292", "ReferenceId": "28213364", "FullCitation": "Rathkopf DE, et al. Clin. Cancer Res. (2017) pmid: 28213364", "Include": "true"}, {"number": "293", "ReferenceId": "24042123", "FullCitation": "Soh SF, et al. J Pharm Biomed Anal (2014) pmid: 24042123", "Include": "true"}, {"number": "294", "ReferenceId": "24169353", "FullCitation": "Bianchini D, et al. Br. J. Cancer (2013) pmid: 24169353", "Include": "true"}, {"number": "295", "ReferenceId": "23939374", "FullCitation": "Li H, et al. Mol. Cancer Ther. (2013) pmid: 23939374", "Include": "true"}, {"number": "296", "ReferenceId": "27683182", "FullCitation": "McKay RR, et al. Clin. Cancer Res. (2017) pmid: 27683182", "Include": "true"}, {"number": "297", "ReferenceId": "24759320", "FullCitation": "Asangani IA, et al. Nature (2014) pmid: 24759320", "Include": "true"}, {"number": "298", "ReferenceId": "26792867", "FullCitation": "Asangani IA, et al. Mol. Cancer Res. (2016) pmid: 26792867", "Include": "true"}, {"number": "299", "ReferenceId": "27707886", "FullCitation": "Faivre EJ, et al. Mol. Cancer Res. (2017) pmid: 27707886", "Include": "true"}, {"number": "300", "ReferenceId": "25908785", "FullCitation": "Chan SC, et al. Nucleic Acids Res. (2015) pmid: 25908785", "Include": "true"}, {"number": "301", "ReferenceId": "31420359", "FullCitation": "Piha_Paul SA, et al. Clin. Cancer Res. (2019) pmid: 31420359", "Include": "true"}, {"number": "302", "ReferenceId": "26527750", "FullCitation": "Montgomery B, et al. Clin. Cancer Res. (2016) pmid: 26527750", "Include": "true"}, {"number": "303", "ReferenceId": "32203070", "FullCitation": "Du M, et al. Prostate Cancer Prostatic Dis (2020) pmid: 32203070", "Include": "true"}, {"number": "304", "ReferenceId": "33990090", "FullCitation": "Dong B, et al. J Natl Compr Canc Netw (2021) pmid: 33990090", "Include": "true"}, {"number": "305", "ReferenceId": "33849963", "FullCitation": "McKay RR, et al. Clin Cancer Res (2021) pmid: 33849963", "Include": "true"}, {"number": "306", "ReferenceId": "16203743", "FullCitation": "Huang G, et al. Hum. Mol. Genet. (2005) pmid: 16203743", "Include": "true"}, {"number": "307", "ReferenceId": "19242095", "FullCitation": "Banck MS, et al. Epigenetics (2009) pmid: 19242095", "Include": "true"}, {"number": "308", "ReferenceId": "9671742", "FullCitation": "Collins C, et al. Proc. Natl. Acad. Sci. U.S.A. (1998) pmid: 9671742", "Include": "true"}, {"number": "309", "ReferenceId": "11245413", "FullCitation": "Nonet GH, et al. Cancer Res. (2001) pmid: 11245413", "Include": "true"}, {"number": "310", "ReferenceId": "17266044", "FullCitation": "Li P, et al. Int. J. Cancer (2007) pmid: 17266044", "Include": "true"}, {"number": "311", "ReferenceId": "22593193", "FullCitation": "Vendrell JA, et al. Cancer Res. (2012) pmid: 22593193", "Include": "true"}, {"number": "312", "ReferenceId": "25031722", "FullCitation": "Li J, et al. Int J Clin Exp Pathol (2014) pmid: 25031722", "Include": "true"}, {"number": "313", "ReferenceId": "22843878", "FullCitation": "Rahman MT, et al. Anticancer Res. (2012) pmid: 22843878", "Include": "true"}, {"number": "314", "ReferenceId": "15701848", "FullCitation": "Yang SH, et al. Clin. Cancer Res. (2005) pmid: 15701848", "Include": "true"}, {"number": "315", "ReferenceId": "25202062", "FullCitation": "Shida A, et al. Anticancer Res. (2014) pmid: 25202062", "Include": "true"}, {"number": "316", "ReferenceId": "15476264", "FullCitation": "Rooney PH, et al. J. Pathol. (2004) pmid: 15476264", "Include": "true"}, {"number": "317", "ReferenceId": "22815235", "FullCitation": "Szczyrba J, et al. Int. J. Cancer (2013) pmid: 22815235", "Include": "true"}, {"number": "318", "ReferenceId": "24853183", "FullCitation": "Geppert CI, et al. Br. J. Cancer (2014) pmid: 24853183", "Include": "true"}, {"number": "319", "ReferenceId": "15897688", "FullCitation": "Toncheva D, et al. Tumour Biol. () pmid: 15897688", "Include": "true"}, {"number": "320", "ReferenceId": "21483406", "FullCitation": "Mao XG, et al. Lab. Invest. (2011) pmid: 21483406", "Include": "true"}, {"number": "321", "ReferenceId": "18193277", "FullCitation": "Schipf A, et al. Virchows Arch. (2008) pmid: 18193277", "Include": "true"}, {"number": "322", "ReferenceId": "17572303", "FullCitation": "Quinlan KG, et al. Biochim. Biophys. Acta (2007) pmid: 17572303", "Include": "true"}, {"number": "323", "ReferenceId": "17259635", "FullCitation": "Krig SR, et al. J. Biol. Chem. (2007) pmid: 17259635", "Include": "true"}, {"number": "324", "ReferenceId": "17130829", "FullCitation": "Cowger JJ, et al. Oncogene (2007) pmid: 17130829", "Include": "true"}, {"number": "325", "ReferenceId": "20661224", "FullCitation": "Krig SR, et al. Oncogene (2010) pmid: 20661224", "Include": "true"}, {"number": "326", "ReferenceId": "21059223", "FullCitation": "Thollet A, et al. Mol. Cancer (2010) pmid: 21059223", "Include": "true"}, {"number": "327", "ReferenceId": "24973012", "FullCitation": "Nguyen NT, et al. Mol Oncol (2014) pmid: 24973012", "Include": "true"}, {"number": "328", "ReferenceId": "24962896", "FullCitation": "Frietze S, et al. BMC Genomics (2014) pmid: 24962896", "Include": "true"}, {"number": "329", "ReferenceId": "22728437", "FullCitation": "Littlepage LE, et al. Cancer Discov (2012) pmid: 22728437", "Include": "true"}, {"number": "330", "ReferenceId": "19935675", "FullCitation": "Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675", "Include": "true"}, {"number": "331", "ReferenceId": "18410249", "FullCitation": "Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249", "Include": "true"}, {"number": "332", "ReferenceId": "12826609", "FullCitation": "Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609", "Include": "true"}, {"number": "333", "ReferenceId": "20978130", "FullCitation": "Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130", "Include": "true"}, {"number": "334", "ReferenceId": "28472496", "FullCitation": "Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496", "Include": "true"}, {"number": "335", "ReferenceId": "17690113", "FullCitation": "Yamada H, et al. Carcinogenesis (2007) pmid: 17690113", "Include": "true"}, {"number": "336", "ReferenceId": "21949389", "FullCitation": "Kumar A, et al. Proc. Natl. Acad. Sci. U.S.A. (2011) pmid: 21949389", "Include": "true"}, {"number": "337", "ReferenceId": "22981675", "FullCitation": "Beltran H, et al. Eur. Urol. (2013) pmid: 22981675", "Include": "true"}, {"number": "338", "ReferenceId": "18552821", "FullCitation": "Schlomm T, et al. Mod. Pathol. (2008) pmid: 18552821", "Include": "true"}, {"number": "339", "ReferenceId": "23609948", "FullCitation": "Liu W, et al. Cancer (2013) pmid: 23609948", "Include": "true"}, {"number": "340", "ReferenceId": "20107315", "FullCitation": "Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315", "Include": "true"}, {"number": "341", "ReferenceId": "21799033", "FullCitation": "Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033", "Include": "true"}, {"number": "342", "ReferenceId": "21389100", "FullCitation": "Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100", "Include": "true"}, {"number": "343", "ReferenceId": "25504633", "FullCitation": "Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633", "Include": "true"}, {"number": "344", "ReferenceId": "12489850", "FullCitation": "Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850", "Include": "true"}, {"number": "345", "ReferenceId": "11713371", "FullCitation": "Xu L, et al. Mol. Med. (2001) pmid: 11713371", "Include": "true"}, {"number": "346", "ReferenceId": "23470564", "FullCitation": "Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564", "Include": "true"}, {"number": "347", "ReferenceId": "25240597", "FullCitation": "Kim SS, et al. Nanomedicine (2015) pmid: 25240597", "Include": "true"}, {"number": "348", "ReferenceId": "27357628", "FullCitation": "Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628", "Include": "true"}, {"number": "349", "ReferenceId": "27601554", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554", "Include": "true"}, {"number": "350", "ReferenceId": "27998224", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224", "Include": "true"}, {"number": "351", "ReferenceId": "31315834", "FullCitation": "Lee J, et al. Cancer Discov (2019) pmid: 31315834", "Include": "true"}, {"number": "352", "ReferenceId": "29535125", "FullCitation": "M\u00e9ndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125", "Include": "true"}, {"number": "353", "ReferenceId": "22446188", "FullCitation": "Ma CX, et al. J. Clin. Invest. (2012) pmid: 22446188", "Include": "true"}, {"number": "354", "ReferenceId": "26563132", "FullCitation": "Kwok M, et al. Blood (2016) pmid: 26563132", "Include": "true"}, {"number": "355", "ReferenceId": "30975914", "FullCitation": "Boudny M, et al. Haematologica (2019) pmid: 30975914", "Include": "true"}, {"number": "356", "ReferenceId": "28062704", "FullCitation": "Dillon MT, et al. Mol. Cancer Ther. (2017) pmid: 28062704", "Include": "true"}, {"number": "357", "ReferenceId": "30127241", "FullCitation": "Middleton FK, et al. Cancers (Basel) (2018) pmid: 30127241", "Include": "true"}, {"number": "358", "ReferenceId": "26014290", "FullCitation": "Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290", "Include": "true"}, {"number": "359", "ReferenceId": "23355100", "FullCitation": "Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100", "Include": "true"}, {"number": "360", "ReferenceId": "11219776", "FullCitation": "Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776", "Include": "true"}, {"number": "361", "ReferenceId": "9006316", "FullCitation": "Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316", "Include": "true"}, {"number": "362", "ReferenceId": "19204208", "FullCitation": "Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208", "Include": "true"}, {"number": "363", "ReferenceId": "12672316", "FullCitation": "Lalloo F, et al. Lancet (2003) pmid: 12672316", "Include": "true"}, {"number": "364", "ReferenceId": "31050713", "FullCitation": "Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2021_10_07 21:22:13", "OpName": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "477x"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "4 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "_1 pca_score"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "Units Not Reported"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "PROSTATE", "disease_ontology": "Prostate acinar adenocarcinoma", "flowcell_analysis": "2000018007", "gender": "male", "pathology_diagnosis": "Prostate cancer; C61", "percent_tumor_nuclei": "60", "pipeline_version": "v3.8.1", "purity_assessment": "62.6", "specimen": "ORD_1201785_01*US1160952.01", "study": "CLINICAL_F1CDx", "test_request": "ORD_1201785_01", "test_type": "FoundationOneDx", "tissue_of_origin": "Liver", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "DX1", "mean_exon_depth": "552.68", "name": "SQ_US1160952.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.6165", "cds_effect": "376_1G>C", "depth": "266", "equivocal": "false", "functional_effect": "splice", "gene": "TP53", "percent_reads": "61.65", "position": "chr17:7578555", "protein_effect": "splice site 376_1G>C", "status": "likely", "strand": "_", "transcript": "NM_000546", "dna_evidence": {"sample": "SQ_US1160952.01_1"}}, {"allele_fraction": "0.5267", "cds_effect": "718G>A", "depth": "393", "equivocal": "false", "functional_effect": "missense", "gene": "CCND2", "percent_reads": "52.67", "position": "chr12:4398154", "protein_effect": "V240M", "status": "unknown", "strand": "+", "transcript": "NM_001759", "dna_evidence": {"sample": "SQ_US1160952.01_1"}}, {"allele_fraction": "0.1572", "cds_effect": "1432G>A", "depth": "4204", "equivocal": "false", "functional_effect": "missense", "gene": "RAF1", "percent_reads": "15.72", "position": "chr3:12627284", "protein_effect": "E478K", "status": "known", "strand": "_", "transcript": "NM_002880", "dna_evidence": {"sample": "SQ_US1160952.01_1"}}, {"allele_fraction": "0.3571", "cds_effect": "2221A>T", "depth": "280", "equivocal": "false", "functional_effect": "missense", "gene": "KDM5A", "percent_reads": "35.71", "position": "chr12:432302", "protein_effect": "T741S", "status": "unknown", "strand": "_", "transcript": "NM_001042603", "dna_evidence": {"sample": "SQ_US1160952.01_1"}}, {"allele_fraction": "0.511", "cds_effect": "449T>C", "depth": "362", "equivocal": "false", "functional_effect": "missense", "gene": "AXL", "percent_reads": "51.1", "position": "chr19:41727824", "protein_effect": "V150A", "status": "unknown", "strand": "+", "transcript": "NM_001699", "dna_evidence": {"sample": "SQ_US1160952.01_1"}}, {"allele_fraction": "0.3141", "cds_effect": "1652A>G", "depth": "503", "equivocal": "false", "functional_effect": "missense", "gene": "REL", "percent_reads": "31.41", "position": "chr2:61149462", "protein_effect": "N551S", "status": "unknown", "strand": "+", "transcript": "NM_002908", "dna_evidence": {"sample": "SQ_US1160952.01_1"}}, {"allele_fraction": "0.5331", "cds_effect": "187G>T", "depth": "332", "equivocal": "false", "functional_effect": "missense", "gene": "NKX2_1", "percent_reads": "53.31", "position": "chr14:36988376", "protein_effect": "A63S", "status": "unknown", "strand": "_", "transcript": "NM_003317", "dna_evidence": {"sample": "SQ_US1160952.01_1"}}, {"allele_fraction": "0.8214", "cds_effect": "7418A>G", "depth": "336", "equivocal": "false", "functional_effect": "missense", "gene": "MLL", "percent_reads": "82.14", "position": "chr11:118374034", "protein_effect": "Y2473C", "status": "unknown", "strand": "+", "transcript": "NM_005933", "dna_evidence": {"sample": "SQ_US1160952.01_1"}}, {"allele_fraction": "0.1553", "cds_effect": "1866G>T", "depth": "676", "equivocal": "false", "functional_effect": "missense", "gene": "SF3B1", "percent_reads": "15.53", "position": "chr2:198267491", "protein_effect": "E622D", "status": "known", "strand": "_", "transcript": "NM_012433", "dna_evidence": {"sample": "SQ_US1160952.01_1"}}, {"allele_fraction": "0.1512", "cds_effect": "1418_1G>A", "depth": "4035", "equivocal": "false", "functional_effect": "splice", "gene": "RAF1", "percent_reads": "15.12", "position": "chr3:12627299", "protein_effect": "splice site 1418_1G>A", "status": "unknown", "strand": "_", "transcript": "NM_002880", "dna_evidence": {"sample": "SQ_US1160952.01_1"}}]}, "copy_number_alterations": {"copy_number_alteration": [{"copy_number": "8", "equivocal": "true", "gene": "NBN", "number_of_exons": "16 of 16", "position": "chr8:90947760_90996835", "ratio": "2.14", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1160952.01_1"}}, {"copy_number": "35", "equivocal": "false", "gene": "TGFBR2", "number_of_exons": "8 of 8", "position": "chr3:30648360_30733091", "ratio": "8.28", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1160952.01_1"}}, {"copy_number": "9", "equivocal": "false", "gene": "MYD88", "number_of_exons": "5 of 5", "position": "chr3:38180152_38182777", "ratio": "2.04", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1160952.01_1"}}, {"copy_number": "8", "equivocal": "true", "gene": "GNAS", "number_of_exons": "13 of 15", "position": "chr20:57466781_57485884", "ratio": "2.06", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1160952.01_1"}}, {"copy_number": "19", "equivocal": "false", "gene": "AR", "number_of_exons": "9 of 9", "position": "chrX:66430630_66980746", "ratio": "4.0", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1160952.01_1"}}, {"copy_number": "30", "equivocal": "false", "gene": "VHL", "number_of_exons": "5 of 5", "position": "chr3:10142940_10285897", "ratio": "7.11", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1160952.01_1"}}, {"copy_number": "51", "equivocal": "false", "gene": "ZNF217", "number_of_exons": "4 of 4", "position": "chr20:52188273_52199365", "ratio": "11.79", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1160952.01_1"}}, {"copy_number": "9", "equivocal": "false", "gene": "MYCN", "number_of_exons": "5 of 5", "position": "chr2:16032653_16136312", "ratio": "2.3", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1160952.01_1"}}, {"copy_number": "9", "equivocal": "false", "gene": "IRS2", "number_of_exons": "5 of 5", "position": "chr13:110406186_110438400", "ratio": "2.64", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1160952.01_1"}}, {"copy_number": "62", "equivocal": "false", "gene": "RAF1", "number_of_exons": "16 of 16", "position": "chr3:12576837_12709494", "ratio": "14.32", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1160952.01_1"}}, {"copy_number": "9", "equivocal": "false", "gene": "FBXW7", "number_of_exons": "11 of 13", "position": "chr4:153143868_153273882", "ratio": "2.3", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1160952.01_1"}}, {"copy_number": "53", "equivocal": "false", "gene": "PPARG", "number_of_exons": "8 of 8", "position": "chr3:12393067_12475644", "ratio": "12.38", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1160952.01_1"}}, {"copy_number": "9", "equivocal": "false", "gene": "SETD2", "number_of_exons": "21 of 21", "position": "chr3:47058582_47205443", "ratio": "2.1", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1160952.01_1"}}, {"copy_number": "9", "equivocal": "false", "gene": "MLH1", "number_of_exons": "19 of 19", "position": "chr3:36976796_37170880", "ratio": "2.36", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1160952.01_1"}}]}, "rearrangements": {"rearrangement": [{"description": "ZNF217(NM_006526) rearrangement exon 1", "equivocal": "false", "in_frame": "unknown", "other_gene": "N/A", "pos1": "chr20:52199335_52199504", "pos2": "chr20:52544214_52544649", "status": "unknown", "supporting_read_pairs": "46", "targeted_gene": "ZNF217", "type": "rearrangement", "dna_evidence": {"sample": "SQ_US1160952.01_1"}}, {"description": "VHL(NM_000551) rearrangement exon 3", "equivocal": "false", "in_frame": "unknown", "other_gene": "N/A", "pos1": "chr3:10191323_10191468", "pos2": "chrX:129565018_129565503", "status": "likely", "supporting_read_pairs": "55", "targeted_gene": "VHL", "type": "truncation", "dna_evidence": {"sample": "SQ_US1160952.01_1"}}]}, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "3.78", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": null}}}}